1
|
Yesildagli B, Göktaş RK, Ayaz T, Olgun B, Dokumacı EN, Özkaleli M, Erdem A, Yurtsever M, Doğan G, Yurdakul S, Yılmaz Civan M. Phthalate ester levels in agricultural soils of greenhouses, their potential sources, the role of plastic cover material, and dietary exposure calculated from modeled concentrations in tomato. J Hazard Mater 2024; 468:133710. [PMID: 38364582 DOI: 10.1016/j.jhazmat.2024.133710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 01/29/2024] [Accepted: 02/01/2024] [Indexed: 02/18/2024]
Abstract
Soil samples collected from 50 greenhouses (GHs) cultivated with tomatoes (plastic-covered:24, glass-covered:26), 5 open-area tomato growing farmlands, and 5 non-agricultural areas were analyzed in summer and winter seasons for 13 PAEs. The total concentrations (Σ13PAEs) in the GHs ranged from 212 to 2484 ng/g, wheeas the concentrations in open-area farm soils were between 240 and 1248 ng/g. Σ13PAE in non-agricultural areas was lower (35.0 - 585 ng/g). PAE exposure through the ingestion of tomatoes cultivated in GH soils and associated risks were estimated with Monte Carlo simulations after calculating the PAE concentrations in tomatoes using a partition-limited model. DEHP was estimated to have the highest concentrations in the tomatoes grown in both types of GHs. The mean carcinogenic risk caused by DEHP for tomato grown in plastic-covered GHs, glass-covered GHs, and open-area soils were 2.4 × 10-5, 1.7 × 10-5 and 1.1 × 10-5, respectively. Based on Positive Matrix Factorization results, plastic material usage in GHs (including plastic cover material source for plastic-GHs) was found to be the highest contributing source in both types of GHs. Microplastic analysis indicated that the ropes and irrigation pipes inside the GHs are important sources of PAE pollution. Pesticide application is the second highest contributing source.
Collapse
Affiliation(s)
- Berkay Yesildagli
- Department of Environmental Engineering, Kocaeli University, Umuttepe Campus, 41001 Kocaeli, Turkey
| | - Recep Kaya Göktaş
- Department of Environmental Engineering, Kocaeli University, Umuttepe Campus, 41001 Kocaeli, Turkey.
| | - Tuğba Ayaz
- Department of Environmental Engineering, Kocaeli University, Umuttepe Campus, 41001 Kocaeli, Turkey
| | - Bihter Olgun
- Department of Environmental Engineering, Akdeniz University, Antalya 07058, Turkey
| | - Ebru Nur Dokumacı
- Department of Environmental Engineering, Akdeniz University, Antalya 07058, Turkey
| | - Merve Özkaleli
- Department of Environmental Engineering, Akdeniz University, Antalya 07058, Turkey
| | - Ayça Erdem
- Department of Environmental Engineering, Akdeniz University, Antalya 07058, Turkey
| | - Meral Yurtsever
- Department of Environmental Engineering, Sakarya University, 54187, Sakarya, Turkey
| | - Güray Doğan
- Department of Environmental Engineering, Akdeniz University, Antalya 07058, Turkey
| | - Sema Yurdakul
- Department of Environmental Engineering, Süleyman Demirel University, Isparta, Turkey
| | - Mihriban Yılmaz Civan
- Department of Environmental Engineering, Kocaeli University, Umuttepe Campus, 41001 Kocaeli, Turkey
| |
Collapse
|
2
|
Çetinkaya B, Erkent S, Ekinci K, Civan M, Bilgili ME, Yurdakul S. Effect of torrefaction on fuel properties of biopellets. Heliyon 2024; 10:e23989. [PMID: 38298728 PMCID: PMC10827685 DOI: 10.1016/j.heliyon.2024.e23989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 12/18/2023] [Accepted: 01/02/2024] [Indexed: 02/02/2024] Open
Abstract
The study aimed to determine the effects of torrefaction on the fuel properties of pellets. Therefore, firstly, torrefaction parameters of rose (Rosa Damascena Mill.) oil distillation solid waste and red pine sawdust were determined through the torrefaction optimization process in terms of temperature and holding time. Then, using the selected torrefaction parameters, 14 different raw and torrefied pellets containing RP, PS, and Turkish Elbistan Lignite were prepared in different weight ratios. Finally, the fuel properties of the prepared raw and torrefied pellets, namely dimensions, proximate analyses, higher heating values, tensile strength, durability, abrasive resistance, and water uptake resistances, were investigated. The findings demonstrated that the higher heating values and carbon content of raw biomass samples increased while their volatile matter content decreased. The use of lignite at high concentrations led to an increase in ash content and a decrease in the strength and durability of pellets, which should be emphasized. In addition, red pine sawdust was used in place of solid waste from rose oil distillation solid waste to produce pellets with greater strength. All pellet mixtures with torrefaction had higher heating values and energy densities despite the fact that their mass and energy efficiency had decreased. It was determined that torrefaction increased the pellets' resistance to absorbing water and gave them a more hydrophobic structure. Thus, it was determined that torrefaction could enhance the crucial fuel parameters of the biomass samples.
Collapse
Affiliation(s)
- Büşra Çetinkaya
- Environmental Engineering Department, Suleyman Demirel University, Isparta, 32000, Turkey
| | - Sena Erkent
- Environmental Engineering Department, Suleyman Demirel University, Isparta, 32000, Turkey
| | - Kamil Ekinci
- Agricultural Machinery and Technology Engineering Department, Isparta University of Applied Sciences, Isparta, 32000, Turkey
| | - Mihriban Civan
- Environmental Engineering Department, Kocaeli University, Kocaeli, 41380, Turkey
| | | | - Sema Yurdakul
- Environmental Engineering Department, Suleyman Demirel University, Isparta, 32000, Turkey
| |
Collapse
|
3
|
Varol M, Gürel B, Yurdakul S, Kurtuluş K, Gürbüz H. PCDD/Fs, PAHs and HCl emissions from co-combustion of lignite and chicken manure in a circulating fluidized bed boiler with compact refractory casting. Waste Manag 2023; 168:423-430. [PMID: 37390797 DOI: 10.1016/j.wasman.2023.06.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 06/02/2023] [Accepted: 06/22/2023] [Indexed: 07/02/2023]
Abstract
Chicken manure (CM) should be used in energy production due to its high production potential for the waste-to-energy approach. Co-combustion of CM with lignites may be a good practice in terms of reducing its environmental impact and the need for fossil fuels. However, the level of organic pollutants originated from CM combustion is not clear. This study investigated the potential of CM to be combusted in a circulating fluidized bed boiler (CFBB) with a local lignite. Combustion and co-combustion tests of CM and Kale Lignite (L) were performed in the CFBB to measure PCDD/Fs, PAHs and HCl emissions. CM burned in the upper parts of the boiler due to its high volatile matter content and low density compared to coal. This caused the bed temperature to decrease with the increase in the amount of CM in the fuel mixture. It was also observed that the combustion efficiency increased as the share of CM in the fuel mixture increased. Total PCDD/F emissions increased with CM share in the fuel mixture. However, all are less than emission limit value (100 pg I-TEQ/m3). Co-combustion of CM with lignite at different ratios did not have a significant effect on HCl emissions. PAH emissions were found to increase with the increase of the CM share when the CM share was more than 50% by weight.
Collapse
Affiliation(s)
- Murat Varol
- Department of Environmental Engineering, Akdeniz University, Antalya 07070, Türkiye.
| | - Barış Gürel
- Mechanical Engineering Department, Süleyman Demirel University, Isparta, Türkiye.
| | - Sema Yurdakul
- Environmental Engineering Department, Süleyman Demirel University, Isparta, Türkiye.
| | - Karani Kurtuluş
- Mechanical Engineering Department, Süleyman Demirel University, Isparta, Türkiye.
| | - Habib Gürbüz
- Automotive Engineering Department, Süleyman Demirel University, Isparta, Türkiye.
| |
Collapse
|
4
|
Celik-Saglam I, Yurtsever M, Civan M, Yurdakul S, Cetin B. Evaluation of levels and sources of microplastics and phthalic acid esters and their relationships in the atmosphere of highly industrialized and urbanized Gebze, Türkiye. Sci Total Environ 2023; 881:163508. [PMID: 37059133 DOI: 10.1016/j.scitotenv.2023.163508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 04/10/2023] [Accepted: 04/10/2023] [Indexed: 06/01/2023]
Abstract
The presence of microplastics (MPs) in the atmosphere and their relationship with other pollutants have been gaining attention due to both their ubiquity and threatening human health. As well phthalic acid esters (PAEs) regarding as plasticizers for being added in plastic materials are key role for plastic pollution. In this study, the concentrations and sources of airborne MPs together with major PAEs and their relationships were investigated for four seasons. MP particles <20 μm, constituting the majority of the samples, were successfully revealed by NR fluorescent analysis. As a result of the μATR-FTIR analyzes, it was seen that besides different polymer derivatives, dye-pigment types, some minerals and compounds, and abundant semi-synthetic fibers and natural fibers were also present. MPs concentration were found in the range of 7207-21,042 MP/m3 in summer, 7245-32,950 MP/m3 in autumn, 4035-58,270 MP/m3 in winter and 7275-37,094 MP/m3 in spring. For the same period, the concentrations of PAEs ranged from 9.24 to 115.21 ng/m3 with an average value of 38.08 ± 7.92 ng/m3. PMF was also applied and four factors were extracted. Factor 1, accounts 52.26 % and 23.27 % of the total PAEs and MPs variances, was attributed to PVC sources. Factor 2, explaining 64.98 % of the total MPs variance had the highest loading of MPs and moderate loadings of relatively low molecular weight of PAEs, was attributed to plastics and personal care products. Factor 3, explaining the 28.31 % of the total PAEs variance was laden with BBP, DnBP, DiBP and DEP and was attributed to various plastic input during the sampling campaign coming from the industrial activities. The last factor accounts for 11.65 % of the total PAEs variance and was dominated by DMEP and it was linked to a source of the activities performed in the laboratories of the university.
Collapse
Affiliation(s)
- Isıl Celik-Saglam
- Gebze Technical University, Department of Environmental Engineering, Gebze, Kocaeli, Turkiye
| | - Meral Yurtsever
- Sakarya University, Department of Environmental Engineering, Sakarya, Turkiye
| | - Mihriban Civan
- Kocaeli University, Department of Environmental Engineering, Kocaeli, Turkiye
| | - Sema Yurdakul
- Suleymen Demirel University, Department of Environmental Engineering, Isparta, Turkiye
| | - Banu Cetin
- Gebze Technical University, Department of Environmental Engineering, Gebze, Kocaeli, Turkiye.
| |
Collapse
|
5
|
Ucar D, Ozyazgan Y, Esatoglu SN, Cerme E, Hamuryudan V, Melikoglu M, Fresko I, Yurdakul S, Yazici H, Hatemi G. AB1308 MYCOPHENOLATE FOR THE TREATMENT OF EYE INVOLVEMENT IN PATIENTS WITH BEHÇET’S SYNDROME. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundExperience with mycophenolate in uveitis associated with Behçet’s syndrome (BS) is limited.ObjectivesWe aimed to report the efficacy and safety of mycophenolate mofetil (MMF) and mycophenolate sodium (MPA) in the treatment of BS uveitis.MethodsAll patients with panuveitis or posterior uveitis who used mycophenolate for eye involvement between 2016 and 2018 were included. Patient charts were reviewed and data on demographic features, previous immunosuppressives, concomitant therapies, ocular attacks and outcome, and adverse events were extracted. Follow up was ended on October 2021.ResultsWe included 12 BS patients (M/W: 8/4, mean age: 35±7 years) treated with mycophenolate during a mean follow-up of 42±19 months (Table 1). All but 3 patients had bilateral eye involvement. IFX and INF-α had been discontinued due to adverse events in all patients, AZA in 10/12, and Cy-A in 7/10.Table 1.Demographic, treatment and outcome of the 12 patientsAge /genderPrevious therapiesRemission induction or Maintenance therapyConcomitant biologicTime to ocular attack (months)Treatment after ocular attackAt the end of the follow-upMMF duration (months)25/MAZA,Cy-ARemission inductionNone2ADA was addedADA and MPAa were switched to INF due to further ocular attacks3842/WAZA,Cy-A, INF, IFXRemission inductionIFXN/AN/AStill on IFX and MMF7237/MAZA,Cy-A, INF, IFX, ADARemission inductionADAN/AN/AStill on ADA and MMF2732/MAZARemission inductionNone12IFX was addedStill on IFX and MMF5233/WAZA, Cy-A, INF, ADA, IFXRemission inductionNoneN/AN/AMPAb was switched to certolizumab and MTX524/MAZARemission inductionIFXN/AN/AStill on MMF and IFX was stopped due to remission6337/MAZA, Cy-ARemission inductionNone6IFX was addedIFX and MMF were switched to INF due to further ocular attacks4136/WAZA,Cy-A, INFMaintenanceNone2ADA was addedStill on ADA and MMF5036/MAZA,Cy-A, INF, IFXMaintenanceIFXN/AN/AStill on IFX and MMF was stopped due to remission1749/WAZA,Cy-A, INFMaintenanceNoneN/AN/AStill on MMF3937/MAZA, INFMaintenanceNone31Cy-A was addedStill on MMF and Cy-A38 d31/MAZA, Cy-A, INFMaintenanceNone5IFX was addedOff treatment for 2 years38a MMF was switched to MPA due to numbness in hands and feet, and MPA was stopped due to arthralgia.b MMF was switched to MPA due to diarrheaSeven patients were prescribed mycophenolate for remission induction. One of these patients had had his first uveitis attack while on AZA treatment due to gastrointestinal involvement. The remaining 6 patients were using other immunosuppressives and experienced relapses that led to mycophenolate use. MMF was added to a biologic agent in 2 patients (IFX and ADA) and was initiated in combination with IFX in 1 patient. These 3 patients did not experience further ocular attacks and IFX was stopped due to remission in 1 patient. In the fourth patient, MMF was switched to MPA due to numbness in hands and feet and MPA was stopped due to arthralgia. This patient did not experience ocular attacks during 5 months of MPA therapy. The remaining 3 patients had further uveitis attacks without decrease in visual acuity 2, 6, and 12 months after MMF initiation, and IFX was added in 2 patients, and ADA in 1 patient. Two of these patients were switched to INF-α due to uveitis relapses. MMF was switched to MPA for diarrhea in 1 patient.Five patients had received MMF for maintenance. One of these was using IFX when MMF was started and these 2 agents were used together. This patient discontinued MMF due to remission 17 months after MMF initiation and is still on IFX monotherapy. The second patient is still on MMF for 39 months without further ocular attacks. ADA, IFX and Cy-A were added in the remaining 3 patients due to ocular attacks 2, 5 and 31 months after MMF initiation. One of these 3 patients stopped IFX and MMF due to remission and is off treatment for 2 years.ConclusionMycophenolate may be an alternative treatment modality in addition to biologics for patients with eye involvement who are intolerant to conventional therapies. Further data is needed to show whether it would be effective when used alone.Disclosure of InterestsDidar Ucar: None declared, Yilmaz Ozyazgan: None declared, Sinem Nihal Esatoglu Speakers bureau: Sinem Nihal Esatoglu has received honorariums for presentations from UCB Pharma, Roche, Pfizer, and Merck Sharp Dohme, Emir Cerme: None declared, Vedat Hamuryudan Speakers bureau: Vedat Hamuryudan has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma, Grant/research support from: Vedat Hamuryudan has received grant/research support from Celgene., Melike Melikoglu: None declared, Izzet Fresko: None declared, Sebahattin Yurdakul: None declared, Hasan Yazici: None declared, Gulen Hatemi Speakers bureau: Gulen Hatemi has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma., Grant/research support from: Gulen Hatemi has received grant/research support from Celgene.
Collapse
|
6
|
Karatemiz G, Esatoglu SN, Gurcan M, Ozguler Y, Yurdakul S, Hamuryudan V, Fresko I, Melikoglu M, Seyahi E, Ugurlu S, Ozdogan H, Yazici H, Hatemi G. AB1305 A SYSTEMATIC REVIEW OF AA AMYLOIDOSIS AMONG PATIENTS WITH BEHÇET’S SYNDROME. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundData on patients with Behçet’s syndrome (BS) complicated with AA amyloidosis is limited to case reports or case series with a small number of patients.ObjectivesIn this study, we aimed to perform a systematic review (SR) of published reports on BS patients with AA amyloidosis.MethodsPubMed and EMBASE were searched with the keywords “Behcet* AND amyloidosis”, without date and language restriction, until May 2020. Two independent reviewers (SNE, GK) performed title/abstract and full text screening and data extraction. A third reviewer (GH) made the final decision in case of disagreement between the two reviewers. Studies that reported patients who were reported by authors as having BS and AA amyloidosis were included. The risk of bias assessment was done using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool.ResultsThe systematic literature search yielded 760 articles of which 703 were excluded after title and abstract review. After full-text review, we further excluded 15 duplicate articles and 1 article was added after handsearching the reference lists of the full texts. Finally, we included 43 articles reporting 96 cases. Among these articles, 38 were case reports and 5 were case series reporting between 6 and 14 patients. All patients but 8 were reported from Mediterranean countries. The quality of all articles according to GRADE was very low due to the lack of a control group.The main features of the patients were male predominance (81/96, 84%), a high frequency of major organ involvement (62/80, 77.5%) especially vascular involvement (60%), a low frequency of comorbidities predisposing to AA amyloidosis (11/96, 11.5%), and a very low frequency of gastrointestinal involvement (3/72, 4%). All but 8 patients were diagnosed with BS and AA amyloidosis simultaneously. The most common presentation was nephrotic syndrome (60/81, 74%). Presenting symptoms other than proteinuria were diarrhea (n=2), acute renal failure (n=2), upper gastrointestinal bleeding (n=1), end stage renal disease (ESRD) (n=1), cardiac symptoms due to cor pulmonale (n=1), and hypertension (n=1). Renal biopsy (72%) and rectal biopsy (17%) were the most commonly used procedures to diagnose AA amyloidosis.After diagnosing AA amyloidosis, colchicine was initiated in 58 patients, cyclophosphamide in 16, and biologics in 3 (1 anakinra and 2 tocilizumab). In the 67 patients with available data on follow-up, 43% of the patients were followed-up for ≤1 year and median follow-up duration was 20 months (IQR: 4-48). Among the 64 patients with available data, 30 (47%) had developed ESRD. Among the 72 patients with available data on survival status, 30 patients (42%) had died. Ten patients (33%) had died within 6 months, 15 had died after a median follow-up of 48 months (IQR: 24-150), and follow-up duration was not available in the remaining 5 patients including 3 patients whose diagnoses were made by autopsy. Reasons for death were infection (n=7), ESRD (n=6), intractable diarrhea (n=3), pulmonary embolism (n=1), cor pulmonale (n=1), hemorrhage due to pulmonary artery aneurysm (n=1), liver cirrhosis (n=1), gastric cancer (n=1), subarachnoid hemorrhage (n=1), and not reported (n=8).ConclusionMale gender and major organ involvement, especially vascular involvement, appear to be risk factors for the development of AA amyloidosis in BS patients. While BS patients complicated with AA amyloidosis have been reported rarely, it is a fatal complication of BS. One third of the patients had died within 6 months after AA amyloidosis diagnosis.Disclosure of InterestsGüzin Karatemiz: None declared, Sinem Nihal Esatoglu Speakers bureau: Sinem Nihal Esatoglu has received honorariums for presentations from UCB Pharma, Roche, Pfizer, and Merck Sharp Dohme., Mert Gurcan: None declared, Yesim Ozguler Speakers bureau: Yesim Ozguler has received honorariums for presentations from UCB Pharma, Novartis, and Pfizer., Sebahattin Yurdakul: None declared, Vedat Hamuryudan Speakers bureau: Vedat Hamuryudan has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma., Grant/research support from: Vedat Hamuryudan has received grant/research support from Celgene., Izzet Fresko: None declared, Melike Melikoglu: None declared, Emire Seyahi Speakers bureau: Emire Seyahi has received honorariums for presentations from Novartis, Pfizer, AbbVie, and Gliead., Serdal Ugurlu: None declared, Huri Ozdogan: None declared, Hasan Yazici: None declared, Gulen Hatemi Speakers bureau: Gulen Hatemi has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma, Grant/research support from: Gulen Hatemi has received grant/research support from Celgene.
Collapse
|
7
|
Esatoglu SN, Tukek B, Taflan SS, Ozyazgan Y, Ucar D, Hamuryudan V, Ozguler Y, Seyahi E, Melikoglu M, Uygunoglu U, Siva A, Kutlubay Z, Fresko I, Yurdakul S, Yazici H, Hatemi G. POS0816 DRUG SURVIVAL OF INFLIXIMAB IN BEHÇET’S SYNDROME PATIENTS WITH DIFFERENT TYPES OF INVOLVEMENT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundInfliximab (IFX) is an effective therapeutic option in the management of severe and refractory manifestations of Behçet’s syndrome (BS).ObjectivesWe aimed to evaluate long term drug survival of IFX in a large cohort of BS patients.MethodsWe reviewed the charts of BS patients who received IFX between 2004 and June 2021 and noted demographic features, reasons for IFX use, IFX duration, and reasons for discontinuation.Results371 patients (290 men, mean age at IFX initiation: 35.5 ± 10 years) received IFX for uveitis (n=164), vascular involvement (n=114), central nervous system (CNS) involvement (n=55), arthritis (n=19), gastrointestinal (GI) involvement (n=15), mucocutaneous involvement (n=10), venous ulcers (n=13), and secondary amyloidosis (n=1). Twenty patients had more than one type of involvement requiring IFX.During a median follow-up of 30 months (IQR: 13-52), 175 (47%) patients were still receiving IFX for a median period of 40 months (IQR: 22-66) while 196 (53%) patients had discontinued IFX after a median follow-up of 19 months (IQR: 8-34).IFX retention rate was 50% for mucocutaneous involvement, 43% for uveitis, 49% for vascular involvement, 58% for CNS involvement, 37% for arthritis, 53% for GI involvement, and 31% for venous ulcer (Table 1).Table 1.Drug survival of infliximab and reasons for infliximab discontinuationMucocutaneous involvement (n=10)Uveitis (n=164)Vascular (n=114)CNS (n=55)Arthritis (n=19)GIS (n=15)Venous ulcer (n=13)Male (n, %)3 (30)127 (77)89 (78)49 (89)14 (74)9 (60)12 (92)Age at infliximab initiation (mean ± SD years)35.8 ± 9.334 ± 9.936 ± 9.136.2 ± 10.439.6 ± 10.743 ± 14.137.4 ± 8.2Number of patients who used concomitant immunosuppressives (n, %)5 (50)108 (66)86 (75)38 (69)5 (26)11 (73)7 (54)Duration of infliximab use (mean ± SD months)33 ± 3845 ± 3828 ± 2337 ± 2837 ± 3526 ± 2625 ± 25Number of patients who discontinued infliximab (n, %)5 (50)93 (57)58 (51)23 (42)12 (63)7 (47)9 (69)Due to remission-30212121Due to primary inefficacy157---5Due to secondary inefficacy212545--Due to adverse event1231211541Due to noncompliance11113--2Due to other reasons-1212311-Reasons for discontinuation were adverse events in 56 (15%), remission in 54 (15%) patients, inefficacy in 45 (12%) (secondary inefficacy in 26 (7%), primary inefficacy in 19 (5%)), and lack of patient compliance in 18 (5%). Other reasons were preparation for surgical operation (n=4), pregnancy (n=4), lack of health insurance (n=4), preferring subcutaneous administration during the pandemic (n=3), due to prison sentence (n=3), willing to get pregnant (n=1), rejecting the treatment (n=1), and death (n=3).Adverse events (n=56) leading to the cessation of IFX were infusion reactions (n=22), infections (n=7), tuberculosis (n=6), malignancy (n=6), palmoplantar psoriasis (n=5), hepatotoxicity (n=4), lichen planus (n=1), drug induced lupus (n=1), auricular chondritis (n=1), macrophage activation syndrome (n=1), splenic infarction (n=1) and a decrease in left ventricular ejection fraction (n=1).At the end of the follow-up, 2 patients had died due to lung adenocarcinoma, 1 patient had died due to pneumosepsis, 1 due to severe parenchymal neurologic involvement and 1 with pulmonary artery involvement due to massive hemorrhage during IFX treatment. Additionally, 7 patients had died 9, 10 months, 3, 3, 4, 7 and 9 years after IFX discontinuation. The causes of death were severe nervous system involvement in 2 patients, right heart failure due to pulmonary hypertension, laryngeal adenocarcinoma, lung adenocarcinoma, sepsis and gastrointestinal bleeding in 1 patient each.ConclusionIFX seems to be effective for the treatment of organ and life-threatening manifestations in the majority of the patients. However, drug retention rate was not optimal, mainly due to adverse events, inefficacy and patient non-compliance.Disclosure of InterestsSinem Nihal Esatoglu Speakers bureau: Sinem Nihal Esatoglu has received honorariums for presentations from UCB Pharma, Roche, Pfizer, and Merck Sharp Dohme, Beyza Tukek: None declared, Sitki Safa Taflan: None declared, Yilmaz Ozyazgan: None declared, Didar Ucar: None declared, Vedat Hamuryudan Speakers bureau: Vedat Hamuryudan has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma, Grant/research support from: Vedat Hamuryudan has received grant/research support from Celgene., Yesim Ozguler Speakers bureau: Yesim Ozguler has received honorariums for presentations from UCB Pharma, Novartis, and Pfizer., Emire Seyahi Speakers bureau: Emire Seyahi has received honorariums for presentations from Novartis, Pfizer, AbbVie, and Gliead, Melike Melikoglu: None declared, Ugur Uygunoglu Speakers bureau: Ugur Uygunoglu has received speaker fees from F Hoffmann La-Roche, F Hoffmann La-Roche, Bayer, Merck-Serono, Novartis, Teva, and Biogen Idec/Gen Pharma of Turkey, Consultant of: Ugur Uygunoglu has received advisory board honorariums from F Hoffmann La-Roche, F Hoffmann La-Roche, Bayer, Merck-Serono, Novartis, Teva, and Biogen Idec/Gen Pharma of Turkey, Aksel Siva Speakers bureau: Aksel Siva received honorariums from Teva for speaking engagements., Consultant of: Aksel Siva received honorariums from Bayer-Schering AG, Biogen/Gen Ilac of Turkey, Genzyme, Merck-Serono, and Roche for consulting, fees from Novartis as a consultant and advisory committee member,., Grant/research support from: Aksel Siva received travel and registration reimbursements from Genzyme., Zekayi Kutlubay: None declared, Izzet Fresko: None declared, Sebahattin Yurdakul: None declared, Hasan Yazici: None declared, Gulen Hatemi Speakers bureau: Gulen Hatemi has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma., Grant/research support from: Gulen Hatemi has received grant/research support from Celgene.
Collapse
|
8
|
Hatemi G, Tukek B, Esatoglu SN, Ozguler Y, Taflan SS, Melikoglu M, Ugurlu S, Fresko I, Kutlubay Z, Yurdakul S, Yazici H, Hamuryudan V. POS0814 OUTCOME OF VASCULAR INVOLVEMENT OF BEHÇET’S SYNDROME TREATED WITH INFLIXIMAB: A RETROSPECTIVE COHORT STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundVascular involvement is the most common cause of mortality and an important cause of disability in patients with Behçet’s syndrome (BS). Cyclophosphamide has been the treatment choice for severe vascular involvement, but high frequency of adverse events such as infertility and infections cause concern. TNF inhibitors can be an alternative for BS patients with vascular involvement.ObjectivesTo survey the efficacy and safety of infliximab (IFX) in BS patients with arterial and venous vascular involvement.MethodsWe reviewed the charts of BS patients who used IFX for vascular involvement. We extracted data on demographic and clinical features, type of vascular involvement, laboratory tests, imaging modalities, concomitant immunosuppressives, duration of IFX use, and outcome. The primary endpoint was remission, defined as the presence of all of the following 3 parameters: 1) lack of new clinical symptoms/findings associated with the vascular lesion 2) normalization of CRP level defined as <10 mg/dl) 3) lack of worsening of the primary vascular lesion or a new lesion vascular at another site on imaging. Remission was assessed at month 6 and month 12. Secondary endpoints were relapse, overall disease activity assessed with BDCAF at baseline and at the final visit, development of new organ involvement other than vascular involvement during IFX treatment, severe adverse events leading to discontinuation of IFX therapy, hospitalization or death, and death.ResultsAmong the 371 patients who used IFX between 2004 and June 2021, 127 patients (102 men, 25 women, mean age 40 ± 8.7 years) had used it for vascular involvement. The types of vascular involvement that required IFX were venous thrombosis in 61 patients (48%), pulmonary artery involvement in 37 (29%), non-pulmonary artery involvement in 16 (13%), and venous ulcer in 13 (10%). Remission rate was 72% (92/127) at month 6 and 61% (71/117) at month 12. 17/99 (17%) patients experienced 22 relapses during a mean follow-up of 28.4±21 months of IFX therapy. Among the 22 relapses, 12 were the progression of the pre-existing vascular lesion and 10 were new vascular lesions. Overall disease activity improved with a decrease in mean BDCAF score from 1.76 ± 1.27 to 0.6 ± 0.8 at the final visit (p<0.001). Remission and relapse rates according to type of vascular involvement and causes of IFX discontinuation are presented in the Table 1. Adverse events leading to IFX discontinuation were infusion reactions in 5, tuberculosis, disseminated zona, lung adenocarcinoma, fibromyxoid sarcoma, heart failure, SLE, palmoplantar pustulosis, auricular chondritis, and aortic stent graft infection in 1 patient each.Table 1.The frequency of concomitant immunosuppressive use, duration of infliximab use and outcomes of BS patients with vascular involvement treated with IFXVenous thrombosis (n=61)Pulmonary artery involvement (n=37)Non-pulmonary arterial involvement (n=16)Venous ulcers (n=13)Overall (n=127)Number of patients who used concomitant immunosuppressives48 (79)24 (65)14 (87)7 (54)93 (73)Duration of IFX use (mean ± SD months)24 ± 19.725 ± 19.335 ± 29.626 ± 2425 ± 21Remission rate at month 650 (82)31 (84)10 (63)1 (8)92 (72)Remission rate at month 12a40 (70)21 (64)8 (53)2 (17)71 (60)Relapse rate4 (7)4 (11)9 (60)017 (13)Number of patients who discontinued IFX31 (51)23 (62)5 (31)9 (69)68 (54)Due to remission1560122Due to inefficacy313411Due to relapse10102Due to adverse event741113Due to noncompliance340310Due to new organ development10001Due to other reasonsb18009Death22004a Since 10 patients did not reach the 12th month yet, the percentages were calculated on 117 patients.b Other reasons were preparation for surgical operation (n=2), not wanting to come to the infusion frequently during the pandemic (n=2), pregnancy (n=1), willing to get pregnant (n=1), lack of health insurance (n=1), due to prison sentence (n=1), and death (n=1).ConclusionInfliximab may be beneficial in BS patients with vascular involvement, even in those who are refractory to immunosuppressives and corticosteroids.Disclosure of InterestsGulen Hatemi Speakers bureau: Gulen Hatemi has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma, Grant/research support from: Gulen Hatemi has received grant/research support from Celgene, Beyza Tukek: None declared, Sinem Nihal Esatoglu Speakers bureau: Sinem Nihal Esatoglu has received honorariums for presentations from UCB Pharma, Roche, Pfizer, and Merck Sharp Dohme., Yesim Ozguler Speakers bureau: Yesim Ozguler has received honorariums for presentations from UCB Pharma, Novartis, and Pfizer., Sitki Safa Taflan: None declared, Melike Melikoglu: None declared, Serdal Ugurlu: None declared, Izzet Fresko: None declared, Zekayi Kutlubay: None declared, Sebahattin Yurdakul: None declared, Hasan Yazici: None declared, Vedat Hamuryudan Speakers bureau: Vedat Hamuryudan has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma, Grant/research support from: Vedat Hamuryudan has received grant/research support from Celgene.
Collapse
|
9
|
Nayak Y, Chakradhari S, Patel KS, Patel RK, Yurdakul S, Saathoff H, Martín-Ramos P. Distribution, Variations, Fate and Sources of Polycyclic Aromatic Hydrocarbons and Carbon in Particulate Matter, Road Dust, and Sediments in Central India. Polycycl Aromat Compd 2022. [DOI: 10.1080/10406638.2022.2026991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Yogita Nayak
- School of Studies in Chemistry, Pandit Ravishankar Shukla University, Raipur, India
| | - Suryakant Chakradhari
- School of Studies in Environmental Science, Pt. Ravishankar Shukla University, Raipur, India
| | | | - Raj Kishore Patel
- Department of Chemistry, National Institute of Technology Rourkela, Sundargarh, Odisha, India
| | - Sema Yurdakul
- Environmental Engineering Department, Suleyman Demirel University, Isparta, Turkey
| | - Harald Saathoff
- Institute of Meteorology and Climate Research, Atmospheric Aerosol Research, Karlsruhe Institute of Technology, Karlsruhe, Germany
| | - Pablo Martín-Ramos
- Instituto de Investigación en Ciencias Ambientales de Aragón (IUCA), EPS, Universito Zaragoza, Carretera de Cuarte, s/n, Huesca, Spain
| |
Collapse
|
10
|
Yurdakul S, Gürel B, Varol M, Gürbüz H, Kurtuluş K. Investigation on thermal degradation kinetics and mechanisms of chicken manure, lignite, and their blends by TGA. Environ Sci Pollut Res Int 2021; 28:63894-63904. [PMID: 33538971 DOI: 10.1007/s11356-021-12732-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Accepted: 01/26/2021] [Indexed: 06/12/2023]
Abstract
In this study, thermogravimetric analysis (TGA) was performed under the air environment for four different heating rates (10, 20, 30, and 40 °C min-1) in order to find out thermal degradation and mechanisms of the chicken manure, a Turkish lignite, and their blends (25 lignite + 75 manure, 50 lignite + 50 manure, and 75 lignite + 25 manure). To calculate thermal kinetics and responsible solid-state mechanisms of the samples, the Flynn-Wall-Ozawa and Coats-Redfern methods were applied. Significant differences between Turkish lignite and chicken manure samples were observed in terms of thermal kinetics and mechanisms. D1 and D4 mechanisms were found to be the responsible mechanisms for the main oxidation region of the lignite and chicken manure/blends, respectively. A similar decreasing trend for the calculated activation energies and pre-exponential constants was observed with increasing biomass content in the manure blends from 25 to 75% by both Flynn-Wall-Ozawa and Coats-Redfern methods. Furthermore, biomass content has an effect on the mechanisms of chicken manure blends during the combustion. D3 was found to be the responsible solid-state mechanism for the third regions (pre-combustion of the manure) of the chicken manure samples. However, D1 and D2 mechanisms were found to be responsible mechanisms for the blends.
Collapse
Affiliation(s)
- Sema Yurdakul
- Environmental Engineering Department, Süleyman Demirel University, Isparta, Turkey.
| | - Barış Gürel
- Mechanical Engineering Department, Süleyman Demirel University, Isparta, Turkey
| | - Murat Varol
- Environmental Engineering Department, Akdeniz University, Antalya, Turkey
| | - Habib Gürbüz
- Automotive Engineering Department, Süleyman Demirel University, Isparta, Turkey
| | - Karani Kurtuluş
- Mechanical Engineering Department, Süleyman Demirel University, Isparta, Turkey
| |
Collapse
|
11
|
Tukek B, Esatoglu SN, Hatemi G, Caliskan EB, Ozyazgan Y, Ucar D, Ozguler Y, Seyahi E, Melikoglu M, Uygunoglu U, Siva A, Kutlubay Z, Fresko I, Yurdakul S, Yazici H, Hamuryudan V. POS0819 EMERGENCE OF DE NOVO MANIFESTATIONS DURING INFLIXIMAB TREATMENT IN BEHÇET SYNDROME. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Infliximab (IFX) is increasingly used in the management of severe, relapsing or refractory manifestations of Behçet Syndrome (BS). Emergence of de novo manifestations have been reported during IFX treatment, despite efficacy for the initial manifestation that required IFX use1.Objectives:We aimed to survey a sizeable cohort of BS patients treated with IFX for the development of de novo manifestations during treatment.Methods:A chart review was conducted to identify all BS patients who were given IFX in our Behçet Disease Research Center between 2004 and 2020. Demographic data, indications for IFX initiation, concomitant drugs, prior treatments, and outcomes were recorded. De novo manifestations were defined as new BS manifestations that had not occurred before IFX treatment.Results:A total of 252 patients used IFX with the main indications being uveitis in 122, vascular involvement in 82, parenchymal central nervous system involvement in 32, gastrointestinal involvement in 11, arthritis in 10, mucocutaneous involvement in 4, and secondary amyloidosis in 1. Of these patients, 17 (6%) had developed a total of 21 de-novo manifestations during a mean follow-up of 38.4 ± 92 (SD) months (Table 1). Vascular involvement was the main indication for IFX in the majority (n=12; 71%) of these 17 patients followed by eye involvement (n=3; 18%), central nervous system involvement (n=1), and joint involvement (n=1). Concomitant medications were prednisolone in 14 patients, azathioprine in 6 patients, mycophenolate mofetil, cyclosporine-A and methotrexate in 1 patient each. Thirteen patients (76%) were in remission for the main indication when de-novo manifestations emerged. In 10 patients IFX treatment was intensified either by increasing the dose to 10 mg/kg (2 patients) or by shortening the infusion intervals to 4 weeks (2 patients) along with the addition of corticosteroids or immunosuppressives. In the remaining 7 patients IFX was switched to another agent (cyclophosphamide in 5, adalimumab in 1 and anakinra in 1). At the time of this survey 8/17 patients were still on IFX for a mean follow-up of 32.5 ± 24.6 (SD) months, with concomitant low dose prednisolone in 5, azathioprine in 3 and mycophenolate mofetil in 3. In addition to the 7 patients who discontinued IFX at the time of de-novo manifestations, 2 more patients had discontinued IFX due to allergic reactions.Conclusion:De novo manifestations developed during IFX treatment in 6% of BS patients, despite efficacy for the initial manifestation. Appearance of de novo manifestations mostly in patients with vascular involvement is noteworthy. Intensification of IFX treatment was efficacious in managing de novo manifestations in more than half of these patients.References:[1]Hamuryudan V et al. Semin Arthritis Rheum. 2015;45(3):369-73.Table 1.Distribution of de novo manifestations that have emerged in 17 patientsDe-novo manifestations21Pulmonary artery aneurysm1Pulmonary artery thrombosis2Coronary artery involvement3Superficial thrombophlebitis5Arthritis5Erythema nodosum3Gastrointestinal involvement1Central nervous system involvement1Disclosure of Interests:None declared
Collapse
|
12
|
Esatoglu SN, Tukek B, Taflan SS, Ozyazgan Y, Ucar D, Hamuryudan V, Ozguler Y, Seyahi E, Melikoglu M, Uygunoglu U, Siva A, Kutlubay Z, Fresko I, Yurdakul S, Yazici H, Hatemi G. POS0814 DRUG RETENTION RATE, REASONS FOR DISCONTINUATION AND OUTCOME OF INFLIXIMAB USE IN BEHÇET SYNDROME. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Infliximab (IFX) plays a key role in the management of severe and refractory manifestations of Behçet syndrome (BS). However we had previously shown that its sustained use may be limited due to adverse events and lack of patient compliance (1).Objectives:To assess the retention rate of IFX, adverse events, causes of discontinuation and outcome after cessation of IFX in a larger group of BS patients who were followed in a tertiary center.Methods:The charts of BS patients who were prescribed IFX between 2004 and 2020 were reviewed to determine demographic features, reasons for IFX use, previous and concomitant drugs, IFX duration, reasons for cessation of IFX and time to flare following cessation of IFX. Follow-up was censored on March 2020.Results:A total of 252 patients (195 men, mean age 40±10 years) received IFX for uveitis (n=122), vascular involvement (n=82), parenchymal neurologic involvement (n=32), gastrointestinal involvement (n=11), arthritis (n=10), mucocutaneous involvement (n=4), and secondary amyloidosis (n=1). Ten patients had more than 1 involvement requiring IFX.During a median follow-up of 52 (IQR: 30-88) months, 122 (48%) patients were still receiving IFX for a median period of 33 (IQR: 15-56) months while 130 (52%) patients had discontinued IFX after a median follow-up of 17 (IQR: 7-31) months. Reasons for discontinuation were remission in 25 (19%) patients, adverse events in 39 (30%), lack of efficacy in 23 (18%) (4 primary and 19 secondary), lack of patient compliance in 36 (28%), pregnancy in 4, and preparation for surgery in 3 patients.Adverse events (n=39) that required the cessation of IFX were infusion reaction (n=17), infection (n=7), hepatotoxicity (n=4), malignancy (n=4), palmoplantar psoriasis (n=3), lichen planus (n=1), drug induced lupus (n=1), splenic infarction (n=1), and a decrease in left ventricular ejection fraction (n=1).Among the 25 patients who discontinued IFX due to remission, 5 (20%) had a relapse after 4, 21, 26, 29, 38 and 46 months. The remaining patients did not experience a relapse during a median follow-up of 35 (IQR: 24-68) months.At the end of the follow-up, 2 patients had died due to lung adenocarcinoma during IFX treatment and 3 patients had died 1 year, 3 and 8 years after IFX discontinuation. The causes of death were with right heart failure due to pulmonary hypertension in 1, and severe nervous system involvement in 2 of the patients.Conclusion:Despite its successful use for the management of potentially organ and life-threatening manifestations in more than half of our patients with BS, long term maintenance was not possible in 42%, mainly due to adverse events, lack of patient compliance and inefficacy.Reference:[1]Esatoglu SN, Tukek B, Taflan SS, et al. SAT0258 Drug Retention Rate and Prognosis After Discontinuation of Infliximab in Patients with Behçet Syndrome. Annals of the Rheumatic Diseases 2020;79: 1071-1072.Reasons for infliximab treatmentNo of patientsNo (%) of patients who were still receiving infliximabNumber (%) of patients who discontinued infliximabReasons for discontinuationDuration of infliximab use(median (IQR) months)Eye involvement12259 (48)63 (52)Remission (n=17)Inefficacy (n=10)Lack of patient compliance (n=19)Adverse event (n=12)Others (n)=5)28 (12.5-52)Vascular involvement8240 (49)42 (51)Remission (n=10)Inefficacy (n=7)Lack of patient compliance (n=12)Adverse event (n=12)Others (n=4)18.5 (9-33.5)Parenchymal neurologic involvement3221 (66)11 (34)Adverse event (n=8)Inefficacy (n=2)Lack of patient compliance (n=1)25 (14.5-50)Gastrointestinal involvement114 (36)7 (64)Remission (n=1)Inefficacy (n=1)Adverse event (n=2)Lack of patient compliance (n=4)7 (2-17)Joint involvement102 (20)8 (80)Inefficacy (n=1)Adverse event (n=5)Lack of patient compliance (n=2)20 (4-35)Mucocutaneous involvement431Inefficacy (n=1)6, 10, 12, 104 monthsAA amyloidosis101Inefficacy (n=1)6 yearsDisclosure of Interests:None declared
Collapse
|
13
|
Hatemi G, Tukek B, Esatoglu SN, Ozguler Y, Melikoglu M, Caliskan EB, Ugurlu S, Fresko I, Yurdakul S, Yazici H, Hamuryudan V. POS0820 INFLIXIMAB FOR VASCULAR INVOLVEMENT IN BEHÇET SYNDROME. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Vascular involvement is an important cause of morbidity and mortality in patients with Behçet syndrome (BS). TNF inhibitors have been reported to be effective for almost all serious manifestations of BS but data on vascular involvement is still limited.Objectives:To survey the efficacy and safety of infliximab (IFX) in BS patients with vascular involvement followed in a dedicated tertiary center.Methods:We reviewed the charts of all BS patients who used IFX and identified those who used this drug for vascular involvement. A standard form was used for extracting data on demographic and clinical features, type of vascular involvement, concomitant immunosuppressives, duration of IFX use, relapses, adverse events and outcome.Results:83 patients (67 men, 16 women, mean age 39.5 ± 8.4 SD years) had used IFX for vascular involvement. The number of patients with each type of vascular involvement as the main indication for IFX, and previous treatment modalities right before IFX are presented in the Table 1. 33 patients had more than 1 type of vascular lesion. Additional organ manifestations were eye involvement in 32, central nervous system involvement in 4 and gastrointestinal involvement in 3 patients. All but one patient used IFX at a dose of 5 mg/kg every 6-8 weeks. All patients used concomitant prednisolone and 51 received pulse methylprednisolone during induction. Other concomitant medications were azathioprine in 21 and mycophenolate mofetil in 4 patients. Outcome of IFX treatment at the end of a mean follow-up of 25.9 months (range 1-103) is tabulated according to arterial and venous involvement (Table 1). Overall, 57/83 (68%) patients obtained remission with no further relapses and IFX could be stopped in 12 (14%) of them. IFX was discontinued due to adverse events in 15 patients. These were allergic reactions in 8, tuberculosis, disseminated zona, lung adenocarcinoma, fibromyxoid sarcoma, heart failure, systemic lupus erythematosus, and palmoplantar pustulosis in 1 patient each. Three patients had died. Causes of death were lung adenocarcinoma in one patient and pulmonary hypertension related right heart failure due to pulmonary artery thrombosis in 2 patients.Conclusion:Infliximab seems to be beneficial in Behçet syndrome patients with vascular involvement, even in those who are refractory to immunosuppressives and corticosteroids. No further relapses occurred in 68% of the patients, and adverse events leading to discontinuation were observed in 18%.Arterial Involvement (n=36)Venous Involvement (n=47)Main reason for infliximab usePulmonary artery aneurysm and/or thrombosis, n=29Peripheral artery aneurysm, n=4Aortic aneurysm, n=3Vena cava superior and/or inferior thrombosis, n=5Lower extremity DVT, n=24Budd-Chiari syndrome, n=4Intracardiac thrombosis, n=2Dural sinus thrombosis, n=7Leg ulcer, n=5Previous treatmentFirst line infliximab413Corticosteroids3438Cyclophosphamide (CYC)25 (15/25 refractory to CYC; 10/25 for maintenance after CYC)11 (8/11 refractory to CYC; 3/11 for maintenance after CYC)Interferon-alpha-13Azathioprine2117Mycophenolate Mofetil12Cyclosporine A-2None due to non-compliance21OutcomeRemission, still on infliximab1623Discontinued due to remission48Discontinued due to adverse events59Discontinued due to relapse53Discontinued due to non-compliance53Died2 (1 had previously discontinued due to relapse)1Disclosure of Interests:None declared
Collapse
|
14
|
Ozguler Y, Hatemi G, Pala AS, Esatoglu SN, Ugurlu S, Seyahi E, Melikoglu M, Fresko I, Ozdogan H, Yurdakul S, Yazici H, Hamuryudan V. POS1351 CAUSES OF HOSPITALIZATION IN BEHÇET SYNDROME. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:The causes of hospitalization may provide important information on the course of diseases and treatment-related adverse effects.Objectives:We aimed to determine the causes and outcome of hospitalizations among patients with Behçet Syndrome (BS) in a dedicated center.Methods:We surveyed hospitalization records in our clinic between January 2002 and December 2019 and identified those with a diagnosis of BS. The records of these patients were reviewed for demographic and clinical features, causes of hospitalization and outcome. We divided hospitalization causes into 2 as being BS related (organ involvement or deterioration) and non-BS related (treatment complication or others).Results:Three-hundred and thirty BS patients (75% men, mean age 37.7 ±11.4 SD years) were hospitalized for a total of 456 times during 18 years. The mean disease duration was 10.8± 8.8 SD years. Two-hundred and ninety-one (64%) patients were using immunosuppressives (IS) with or without corticosteroids (CSs) and 72 (16%) of them were under biologic treatment at the time of hospitalization. The mean duration of hospitalization was 12.7±10.7 SD days. The reasons for hospitalization were directly related to BS in 259 patients (57%) and non-related to BS in 191 (42%). Six patients were hospitalized for both BS and non-BS related reasons at the same time. The most common reasons were vascular involvement (n=169, 64%) for BS related reasons and infections (n=64, 32%) for non-BS related reasons (Table 1). Patients hospitalized for BS related causes were younger (35.2±10.6 vs 41.1±11.7, p<0.001), had short mean disease duration (8.5±7.5 vs. 13.6±9.4 years, p<0.001), stayed shorter in the hospital (11.6±8.6 vs 14.0±12.9 days p=0.03) and had less frequent IS±CSs use (59% vs 70%, p=0.02) compared to those with non-BS related hospitalizations. There were no differences between the groups regarding gender distribution (203 M/62 F vs. 143 M/54 F) and use of biologic agents (15% vs 17%). Three patients died during hospitalization. The reasons were malignancy, infection and right heart failure due to pulmonary artery thrombosis and pulmonary hypertension, respectively.Conclusion:Vascular involvement is the leading cause of hospitalization among BS patients, followed by infections. The predominance of men among hospitalized patients underlines the relatively severe course of BS in men. The retrospective design and inclusion of patients who were hospitalized only in the rheumatology unit are limitations of this study.Table 1.Distributions of BS related and non-BS related reasons of hospitalizationsBS patients hospitalized with BS related reasons(n of pts=195, n of hospitalizations=265)*BS patients hospitalized with non-BS related reasons(n of pts=170, n of hospitalizations=197)*Causes of hospitalizations (per hospitalization)Vascular inv. (n=169, 64 %)Pulmonary artery inv. (n=64, 24 %)Deep vein thrombosis (n=39, 15 %)Budd-Chiari synd. (n=24, 9%)Vena cava inf. thrombosis (n=19, 7 %)Peripheral artery inv. (n=15, 6 %)Vena cava sup. thrombosis (n=14, 5 %)Aorta inv. (n=14, 5%)Coronary artery inv. (n=4, 2 %)Infection (n=64, 32%)Pneumonia (n=17, 8%)Tuberculosis (n=8, 4%)Urinary tract inf (n=7, 4%)Gastroenteritis (n=4, 2%)Osteomyelitis (n=3, 2%)Septic arthritis (n=3, 2%)Aspergillosis (n=2, 1%)Nocardia (n=1, 1%)Salmonella (n=1, 1%)Others (n=18, 9%)Neurologic inv. (n=50, 19 %)Parenchymal inv. (n=37, 14%)Dural sinus thrombosis (n=13, 5%)Drug side effects other than infections (n=29, 15 %)Interferon (n=10, 5%)Azathioprine (n=7, 4%)Cyclosporine (n=5, 3%)Steroid (n=3, 2%)TNF antagonists (n=3, 2%)IVIG (n=1, 1%)GI inv. (n=18, 7%)Additional rheumatologic diseases (n=17, 9%)Joint inv. (n=12, 5%)Renal disease (n=16, 8 %)Mucocutaneous inv. (n=10, 4%)Cardiovascular dis. (n=12, 6%)Eye inv. (n=8, 3%)Avascular necrosis (n=4, 2%)Others (n=8, 3%)Malignancy (n=11, 6%)Others (n=40, 20%)*Some patients were hospitalized more than one times and for both BS related and non-BS related reasons at different time and had more than one type of BS related and/or non-BS related reasons.Disclosure of Interests:None declared
Collapse
|
15
|
Ekinci Z, Civan M, Yurdakul S. Effects of particle size on oxidative thermal decomposition kinetics and mechanisms of selected waste wood samples. CHEM ENG COMMUN 2020. [DOI: 10.1080/00986445.2020.1817743] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Zeliha Ekinci
- Environmental Engineering Department, Suleyman Demirel University, Isparta, Turkey
| | - Mihriban Civan
- Environmental Engineering Department, Kocaeli University, Kocaeli, Turkey
| | - Sema Yurdakul
- Environmental Engineering Department, Suleyman Demirel University, Isparta, Turkey
| |
Collapse
|
16
|
Esatoglu SN, Tukek B, Taflan SS, Ozyazgan Y, Ucar D, Seyahi E, Melikoglu M, Hamuryudan V, Uygunoglu U, Siva A, Fresko I, Yurdakul S, Yazici H, Hatemi G. SAT0258 DRUG RETENTION RATE AND PROGNOSIS AFTER DISCONTINUATION OF INFLIXIMAB IN PATIENTS WITH BEHÇET SYNDROME. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Infliximab (IFX) has become an important treatment option for all manifestations of Behçet syndrome (BS). Adverse events, loss of efficacy, lack of patient compliance and cost may limit its sustained use in patients with BS.Objectives:We aimed to evaluate the drug retention rates, causes of discontinuation and outcome after cessation of IFX.Methods:We reviewed the charts of 850 patients with BS who were registered in our clinic between 2009 and 2013 and identified those who had used IFX. The charts of these patients were surveyed for demographic features, the reasons for IFX use, previous and concomitant drugs, IFX duration, reasons for discontinuation and time to flare after discontinuation of IFX. We defined flare as disease activity in the organ involvement that necessitated IFX use. New major organ involvement that developed during or after discontinuation of IFX were also be noted.Results:A total of 50/850 patients were treated with IFX (40 men, mean age 40±9.5 years), for uveitis (n=29), vascular involvement (n=11), parenchymal neurologic involvement (n=8), arthritis (n=1) and venous ulcer (n=1). Of these 50 patients, 22 (43%) are still receiving IFX for a median duration of 40 (IQR: 25-83) months. The remaining 28 (47%) patients had discontinued IFX after a median follow-up of 12 (IQR: 7-30) months. Reasons for discontinuation were remission in 7 patients, adverse events in 10, primary lack of efficacy in 2, and lack of patient compliance in 9 patients. Among the 7 patients who discontinued IFX due to remission, only 1 patient with uveitis had a flare, 11 months after discontinuation, while on azathioprine. The remaining 6 did not experience any flares during a median follow-up of 29.5 (IQR: 4-24) months. Five of these patients used azathioprine and 1 used mycophenolate mofetil for maintenance. Among the 10 patients who discontinued due to adverse events, IFX was switched to adalimumab in 3 patients and none experienced flares under adalimumab. The remaining 7 patients continued to receive azathioprine or mycophenolate mofetil without a biologic. Among these, 1 patient with uveitis 1 with arthritis experienced flares 6 months after discontinuing IFX. Among the 9 patients who discontinued IFX due to lack of patient compliance, 3 patients (2 with uveitis and 1 with arthritis) had flares after 5 months, 1 year and 1.5 years. IFX was re-initiated in all. The remaining 6 patients did not experience any flares after a mean follow up of 5±1.5 years. Two with uveitis and 2 with venous thrombosis used azathioprine for maintenance, while 2 patients did not receive further treatment. New major organ involvement was not observed. New BS manifestations developed in 2 patients under IFX, arthritis in one patient and both epididymitis and erythema nodosum in the other.Conclusion:Almost half of our patients with BS remained on IFX during a median follow-up of 5.4 years (IQR:2.4-7). Main reasons for discontinuation were adverse events, remission and lack of patient compliance. Our observations further support the efficiency of IFX in managing patients with BS.Disclosure of Interests:Sinem Nihal Esatoglu: None declared, Beyza Tukek: None declared, Sitki Safa Taflan: None declared, Yilmaz Ozyazgan: None declared, Didar Ucar: None declared, Emire Seyahi: None declared, Melike Melikoglu: None declared, Vedat Hamuryudan Speakers bureau: Pfizer, AbbVie, Amgen, MSD, Novartis, UCB, Ugur Uygunoglu: None declared, Aksel Siva: None declared, Izzet Fresko: None declared, Sebahattin Yurdakul: None declared, Hasan Yazici: None declared, Gulen Hatemi Grant/research support from: BMS, Celgene Corporation, Silk Road Therapeutics – grant/research support, Consultant of: Bayer, Eli Lilly – consultant, Speakers bureau: AbbVie, Mustafa Nevzat, Novartis, UCB – speaker
Collapse
|
17
|
Erciyes D, Ozden Tok O, Yurdakul S, Bakan S, Goktekin O. P1490 Congenital right coronary artery fistula into right atrium diagnosed with help of multimodality imaging. Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.914] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Coronary artery fistula (CAF) is an anomaly in which abnormal connections are present between the coronary artery and the cardiac chambers or a major vessel. It is an uncommon anomaly with an estimated incidence of 1 in 50,000 live births and usually occurs in isolation.
We report a case of CAF into right atrium in a patient who admitted to our outpatient department with dyspnea and fatique. With help of transthoracic echocardiography (TTE), transesophageal echocardiography (TOE) and cardiac computerized tomography (CCT) we put the definite diagnosis and decided to close this fistula percutaneously with a PDA occluder.
Case
A 43-year- old male admitted to our outpatient department with complaints of exertional dyspnea and fatique for 5 years. His physical examination revealed a holosystolic murmur on the aortic valve area. His TTE showed enlarged right heart chambers with a high pulmonary artery systolic pressure (50 mmHg) and a suspicious flow from the aortic root into right atrium. Qp/Qs was 2.1. TOE depicted a shunt between aorta and right atrium as well, we couldn’t truly demonstrate the connection though .
In order to define the defect precisely, we performed a cardiac CT. Cardiac CT clearly showed a markedly dilated and mildly tortuous and calcified fistula arising from the osteal part of right coronary artery draining into right atrium. Right coronary artery was thin and there was no stenosis. Cardiac CT helped us to exclude coronary arter disease as well.
As it was suitable to close percutaneously, we decided to close it with a PDA occluder.
Conclusion
CAF is a rare, generally congenital anomaly and may cause right heart chamber dilatation and pulmonary hypertension if the diagnosis is missed. It is important to support and clarify the underlying pathology with help of other cardiovascular imaging modalities like cardiac CT and cardiac magnetic resonance imaging (CMR), if TTE and TOE cannot demonstrate us the exact pathology.In our case our choice of extra method was cardiac CT, as we wanted to exclude accompanying coronary artery disease at the same time. In today’s era, the use of multimodality imaging is increasing with a tremendous rate and it helps clinical cardiologists, cardiovascular imaging specialists and interventional cardiologists all.
Abstract P1490 Figure. 2D,3D TOE and CCT images of CAF
Collapse
Affiliation(s)
- D Erciyes
- Florence Nightingale Hospital, Cardiology, Istanbul, Turkey
| | - O Ozden Tok
- Memorial Bahcelievler Hospital, Istanbul, Turkey
| | - S Yurdakul
- Florence Nightingale Hospital, Cardiology, Istanbul, Turkey
| | - S Bakan
- Memorial Bahcelievler Hospital, Istanbul, Turkey
| | - O Goktekin
- Memorial Bahcelievler Hospital, Istanbul, Turkey
| |
Collapse
|
18
|
Cetin B, Yurdakul S, Odabasi M. Polybrominated diphenyl ethers (PBDEs) pollution in soil of a highly industrialized region (Dilovasi) in Turkey: concentrations, spatial and temporal variations and possible sources. Environ Monit Assess 2019; 191:474. [PMID: 31256268 DOI: 10.1007/s10661-019-7610-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Accepted: 06/18/2019] [Indexed: 06/09/2023]
Abstract
In this study, polybrominated diphenyl ethers (PBDEs) levels in soil were studied for a whole year in highly industrialized region of Turkey (Dilovasi) at 23 sampling sites. Σ8PBDE concentrations were between 0.15 and 286 μg kg-1 and the overall average concentration was 14.45 ± 25.07 μg kg-1 (average ± SD). BDE-209 was the most abundant compound. PBDEs concentrations decreased spatially as follows: industrial/urban > urban > suburban > rural. However, there was not any significant seasonal trend except for some industrial/urban sites. In the region, calm weather conditions prevailed during the sampling periods, enhancing the impact of the industrial emissions on nearby soil concentrations by atmospheric deposition without being diluted by winds. All congeners had significant but weak correlations with soil organic matter content indicating the impact of nearby sources rather than soil properties on soil PBDEs concentrations at the sampling sites. Positive matrix factorization method was also used for the apportionment of the PBDEs sources in Dilovasi soil. Industrial activities (i.e., iron-steel production, metallurgical processes, and recycling of plastics), traffic, and residential areas were found to be the primary sources of the measured PBDEs in the soil.
Collapse
Affiliation(s)
- Banu Cetin
- Environmental Engineering Department, Gebze Technical University (GTU), 41400, Gebze, Kocaeli, Turkey.
| | - Sema Yurdakul
- Environmental Engineering Department, Suleyman Demirel University, 32260, Isparta, Turkey
| | - Mustafa Odabasi
- Environmental Engineering Department, Faculty of Engineering, Dokuz Eylul University, Tinaztepe Campus, 35160 Buca, Izmir, Turkey
| |
Collapse
|
19
|
Cetin B, Yurdakul S, Odabasi M. Spatio-temporal variations of atmospheric and soil polybrominated diphenyl ethers (PBDEs) in highly industrialized region of Dilovasi. Sci Total Environ 2019; 646:1164-1171. [PMID: 30235602 DOI: 10.1016/j.scitotenv.2018.07.299] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/29/2018] [Revised: 06/26/2018] [Accepted: 07/20/2018] [Indexed: 06/08/2023]
Abstract
Polybrominated diphenyl ethers (PBDEs) were investigated in ambient air of a highly industrialized region at 23 different sampling sites for 12 months. Total concentrations of 8 PBDE congeners (Σ8PBDE) were found to be between 5.73 and 520 pg m-3 (94.7 ± 78.9; average ± SD) and BDE-209 was the predominant congener, followed by BDE-47 and/or BDE-99. Their contributions to Σ8PBDE were 71 ± 13, 9 ± 4% and 8 ± 4%; respectively. Compared to previous studies around the world, high concentrations detected in Dilovasi demonstrated the severity of atmospheric PBDE pollution in the area. For all sampling sites, average PBDE concentration obtained in summer (118.5 ± 98.7 pg m-3) was higher than one found in winter period (79.7 ± 59.1 pg m-3) and this seasonal difference was more obvious in industrial/urban sites (p < 0.05), probably due to enhanced volatilization from ongoing PBDE sources such as waste incineration and iron-steel plants. The soil-air exchange tendencies of PBDEs did not show substantial differences between the sampling periods with small variations for each congener. All congeners either tend to deposit to soil or to be within the equilibrium range for all seasons. This reflects the impact of local ongoing sources rather than temperature on the direction of soil-air exchange of PBDEs in this region. Specific congener ratios such as BDE-47/-99 and -99/-100 confirmed the impact of local sources rather than long-range transport on PBDE congeners in the study area. According to the Positive Matrix Factorization (PMF) results, the BDE-209 content of the first factor was found to be 91.7% and this factor was attributed to the deca-BDE technical formulations. The second factor was highly rich with both BDE-183 (%61) and BDE-28 (%52) and identified as octa-BDE technical products. The last factor was highly loaded with BDE-99, BDE-47, BDE-100, BDE-154 and BDE-153 and has been determined as the penta-BDE commercial formulations.
Collapse
Affiliation(s)
- Banu Cetin
- Environmental Engineering Department, Gebze Technical University (GTU), 41400 Gebze, Kocaeli, Turkey.
| | - Sema Yurdakul
- Environmental Engineering Department, Suleyman Demirel University, 32260 Isparta, Turkey
| | - Mustafa Odabasi
- Environmental Engineering Department, Faculty of Engineering, Dokuz Eylul University, Tinaztepe Campus, 35160 Buca, Izmir, Turkey
| |
Collapse
|
20
|
Cetin B, Yurdakul S, Gungormus E, Ozturk F, Sofuoglu SC. Source apportionment and carcinogenic risk assessment of passive air sampler-derived PAHs and PCBs in a heavily industrialized region. Sci Total Environ 2018; 633:30-41. [PMID: 29573689 DOI: 10.1016/j.scitotenv.2018.03.145] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/28/2017] [Revised: 02/22/2018] [Accepted: 03/14/2018] [Indexed: 06/08/2023]
Abstract
Cancer has become the primary reason of deaths in Dilovasi probably due to its location with unique topography under the influence of heavy industrialization and traffic. In this study, possible sources and carcinogenic health risks of PAHs and PCBs were investigated in Dilovasi region by Positive Matrix Factorization (PMF) and the USEPA approach, respectively. PAHs and PCBs were measured monthly for a whole year at 23 sampling sites using PUF disk passive samplers. Average ambient air concentrations were found as 285±431ng/m3 and 4152±6072pg/m3, for Σ15PAH and Σ41PCB, respectively. PAH concentrations increased with decreasing temperature especially at urban sites, indicating the impact of residential heating in addition to industrial activities and traffic. On the other hand, PCB concentrations mostly increased with temperature probably due to enhanced volatilization from their sources. Possible sources of PAHs were found as emissions of diesel and gasoline vehicles, biomass and coal combustion, iron and steel industry, and unburned petroleum/petroleum products, whereas iron-steel production, coal and biomass burning, technical PCB mixtures, and industrial emissions were identified for PCBs. The mean carcinogenic risk associated with inhalation exposure to PAHs and PCBs were estimated to be >10-6 and >10-5, respectively, at all sampling points, while the 95th percentile was >10-5 at 15 of 23 and >10-4 at 8 of 23 sampling locations, respectively. Probabilistic assessment showed, especially for PCBs, that a majority of Dilovasi population face significant health risks. The higher risks due to PCBs further indicated that PCBs and possibly other pollutants originating from the same sources such as PBDEs and PCNs may be an important issue for the region.
Collapse
Affiliation(s)
- Banu Cetin
- Environmental Engineering Department, Gebze Technical University (GTU), 41400 Gebze, Kocaeli, Turkey.
| | - Sema Yurdakul
- Environmental Engineering Department, Suleyman Demirel University, 32260 Isparta, Turkey
| | - Elif Gungormus
- Department of Chemical Engineering, Izmir Institute of Technology, 35430, Gulbahce, Urla, Izmir, Turkey
| | - Fatma Ozturk
- Environmental Engineering Department, Abant Izzet Baysal University (AIBU), 14030 Bolu, Turkey
| | - Sait C Sofuoglu
- Department of Environmental Engineering, Izmir Institute of Technology, 35430, Gulbahce, Urla, Izmir, Turkey
| |
Collapse
|
21
|
Abstract
Purpose This study investigated the pathogenesis of tractional retinal detachment associated with proliferative vitreoretinopathy in an experimental model, using immunohistochemical staining. Methods To produce tractional retinal detachment in rabbit eyes, homologous cultured fibroblasts obtained from the gluteal muscle fascia were injected intravitreously. Right eyes of 20 rabbits in the study group, and 7 rabbits in the control group were followed for 28 days at weekly intervals with indirect ophthalmoscopy and fundus photographs. Results During the follow-up period grade III tractional retinal detachment developed in 11 eyes, grade II in six, and grade 1 in three eyes. The spindle-shaped cells contributed predominantly to the development of epiretinal membrane, and a smaller number of round small and large cells. In 10/17 grade II and III eyes, spindle-shaped cells had vimentin, 7/10 had actin, 5/17 had GFAP, 4/17 had S-100 protein immunoreactivity. Round small and large cells expressed S-100 protein, GFAP and actin in 5/17 eyes. Epiretinal membrane appeared to be formed by spindle-shaped fibroblast-like cells and small and large round glia-like cells. Actin positivity of spindle-shaped and round cells was taken as a marker of contractile elements of the cells and their locomotional features. Conclusions These features are believed to be involved in contraction of the membrane and retinal detachment.
Collapse
Affiliation(s)
- H Basmak
- Ophthalmology Department, Osmangazi University, School of Medicine, Eskisehir, Turkey
| | | | | | | | | |
Collapse
|
22
|
Cetin B, Yurdakul S, Keles M, Celik I, Ozturk F, Dogan C. Atmospheric concentrations, distributions and air-soil exchange tendencies of PAHs and PCBs in a heavily industrialized area in Kocaeli, Turkey. Chemosphere 2017; 183:69-79. [PMID: 28535463 DOI: 10.1016/j.chemosphere.2017.05.103] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Revised: 05/16/2017] [Accepted: 05/17/2017] [Indexed: 06/07/2023]
Abstract
Dilovasi is one of the heavily industrialized areas in Turkey with serious environmental problems. In this study, the atmospheric concentration of PAHs and PCBs were measured for a whole year at 23 sites. The average ambient air Σ15PAH and Σ41PCB concentrations were found as 285 ± 431 ng m-3 and 4152 ± 6072 pg m-3, respectively. PAH concentrations increased with decreasing temperature especially in urban areas, indicating the impact of residential heating. However, PCB concentrations mostly increased with temperature probably due to enhanced volatilization from their sources. The gradient obtained for PCBs, rural < suburban < urban < industrial/urban, is more clear than those obtained for PAHs. The average Σ15PAH and Σ41PCB soil concentrations were found as 992 ± 1323 and 18.8 ± 32.0 μg kg-1, respectively. PCB soil concentrations did not show significant temporal variations while PAH concentrations were variable especially for urban areas. The volatilization tendencies of low and medium molecular weight PAHs from soil to air were higher in industrial-urban areas than rural sites, showing that soil was a secondary source for PAHs. Fugacity ratios of PCBs were mostly <1.0 for the whole sampling period. Although the source/sink tendency of soil for some PCBs depends on their volatility, considering the whole data, PCBs were generally deposited to soil.
Collapse
Affiliation(s)
- Banu Cetin
- Environmental Engineering Department, Gebze Technical University (GTU), 41400, Gebze, Kocaeli, Turkey.
| | - Sema Yurdakul
- Environmental Engineering Department, Suleyman Demirel University, 32260, Isparta, Turkey
| | - Melek Keles
- Environmental Engineering Department, Abant Izzet Baysal University (AIBU), 14030, Bolu, Turkey
| | - Isil Celik
- Environmental Engineering Department, Gebze Technical University (GTU), 41400, Gebze, Kocaeli, Turkey
| | - Fatma Ozturk
- Environmental Engineering Department, Abant Izzet Baysal University (AIBU), 14030, Bolu, Turkey
| | - Cevdet Dogan
- Environmental Engineering Department, Gebze Technical University (GTU), 41400, Gebze, Kocaeli, Turkey
| |
Collapse
|
23
|
Cetin B, Ozturk F, Keles M, Yurdakul S. PAHs and PCBs in an Eastern Mediterranean megacity, Istanbul: Their spatial and temporal distributions, air-soil exchange and toxicological effects. Environ Pollut 2017; 220:1322-1332. [PMID: 27825846 DOI: 10.1016/j.envpol.2016.11.002] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Revised: 11/01/2016] [Accepted: 11/01/2016] [Indexed: 06/06/2023]
Abstract
Istanbul, one of the mega cities in the world located between Asia and Europe, has suffered from severe air pollution problems due to rapid population growth, traffic and industry. Atmospheric levels of PAHs and PCBs were investigated in Istanbul at 22 sampling sites during four different sampling periods using PUF disk passive air samplers and spatial and temporal variations of these chemicals were determined. Soil samples were also taken at the air sampling sites. At all sites, the average ambient air Σ15PAH and Σ41PCB concentrations were found as 85.6 ± 68.3 ng m-3 and 246 ± 122 pg m-3, respectively. Phenanthrene and anthracene were the predominant PAHs and low molecular weight congeners dominated the PCBs. The PAH concentrations were higher especially at urban sites close to highways. However, the PCBs showed moderately uniform spatial variations. Except four sites, the PAH concentrations were increased with decreasing temperatures during the sampling period, indicating the contributions of combustion sources for residential heating, while PCB concentrations were mostly increased with the temperature, probably due to enhanced volatilization at higher temperatures from their sources. The results of the Factor Analysis represented the impact of traffic, petroleum, coal/biomass and natural gas combustion and medical waste incineration plants on ambient air concentrations. A similar spatial distribution trend was observed in the soil samples. Fugacity ratio results indicated that the source/sink tendency of soil for PAHs and PCBs depends on their volatility and temperature; soil generally acts as a source for lighter PAHs and PCBs particularly in higher temperatures while atmospheric deposition is a main source for higher molecular weight compounds in local soils. Toxicological effect studies also revealed the severity of air and soil pollution especially in terms of PAHs in Istanbul.
Collapse
Affiliation(s)
- Banu Cetin
- Environmental Engineering Department, Gebze Technical University (GTU), 41400, Gebze, Kocaeli, Turkey.
| | - Fatma Ozturk
- Environmental Engineering Department, Abant Izzet Baysal University (AIBU), 14030, Bolu, Turkey
| | - Melek Keles
- Environmental Engineering Department, Abant Izzet Baysal University (AIBU), 14030, Bolu, Turkey
| | - Sema Yurdakul
- Environmental Engineering Department, Suleyman Demirel University, 32260, Isparta, Turkey
| |
Collapse
|
24
|
Ayan G, Ugurlu S, Hatemi G, Seyahi E, Melikoglu M, Fresko I, Ozdogan H, Yurdakul S, Hamuryudan V. FRI0372 Rituximab for ANCA Associated Vasculitis Refractory To Conventional Treatment: A Retrospective Study on 25 Patients. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4184] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
25
|
Ugurlu S, Cetinkaya F, Keskin F, Melikoglu M, Hamuryudan V, Fresko I, Kadioglu P, Yurdakul S, Seyahi E. SAT0367 Can We Differentiate Takayasu Arteritis from Atherosclerosis Using Carotid and Femoral Artery Doppler USG?: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
26
|
Esatoglu S, Celik A, Ucar D, Celik A, Ugurlu S, Hatemi G, Melikoglu M, Fresko I, Hamuryudan V, Ozdogan H, Yurdakul S, Yazici H, Seyahi E. AB0573 The Disease Associations of Takayasu's Arteritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
Guzelant G, Ozguler Y, Esatoglu S, Karatemiz G, Ozdogan H, Yurdakul S, Yazici H, Seyahi E. THU0572 Relationship between Menstruation and Symptoms of Behçet's Syndrome:. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
28
|
Hacioglu A, Ozguler Y, Borekci S, Hamuryudan V, Kecebas H, Tascilar E, Melikoglu M, Ugurlu S, Seyahi E, Fresko I, Ozdogan H, Yurdakul S, Ongen G, Hatemi G. SAT0140 How Correct are the Assumptions Made During the Development of Tuberculosis Screening Algorythms Before TNF-Alpha Antagonists? Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.6163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
Ozguler Y, Esatoglu S, Keskin D, Hatemi G, Hamuryudan V, Pala A, Ugurlu S, Tascilar K, Melikoglu M, Seyahi E, Fresko I, Ozdogan H, Yurdakul S, Ongen G, Yazici H. AB0435 Malignancies in Rheumatoid Arthritis Patients Treated with TNF-Alpha Antagonists. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Turco A, Duchenne J, Nuyts J, Gheysens O, Voigt JU, Claus P, Vunckx K, Muhtarov K, Ozer N, Turk G, Sunman H, Karakulak U, Sahiner L, Kaya B, Yorgun H, Hazirolan T, Aytemir K, Warita S, Kawasaki M, Tanaka R, Houle H, Yagasaki H, Nagaya M, Ono K, Noda T, Watanabe S, Minatoguchi S, Kyle A, Dauphin C, Lusson JR, Dragoi Galrinho R, Rimbas R, Ciobanu A, Marinescu B, Cinteza M, Vinereanu D, Dragoi Galrinho R, Ciobanu A, Rimbas R, Marinescu B, Cinteza M, Vinereanu D, Aparina O, Stukalova O, Butorova E, Makeev M, Bolotova M, Parkhomenko D, Golitsyn S, Zengin E, Hoffmann BA, Ramuschkat M, Ojeda F, Weiss C, Willems S, Blankenberg S, Schnabel RB, Sinning CR, Schubert U, Suhai FI, Toth A, Kecskes K, Czimbalmos C, Csecs I, Maurovich-Horvat P, Simor T, Merkely B, Vago H, Slawek D, Chrzanowski L, Krecki R, Binkowska A, Kasprzak JD, Palombo C, Morizzo C, Kozakova M, Charisopoulou D, Koulaouzidis G, Rydberg A, Henein M, Kovacs A, Olah A, Lux A, Matyas C, Nemeth B, Kellermayer D, Ruppert M, Birtalan E, Merkely B, Radovits T, Henri C, Dulgheru R, Magne J, Kou S, Davin L, Nchimi A, Oury C, Pierard L, Lancellotti P, Sahin ST, Cengiz B, Yurdakul S, Altuntas E, Aytekin V, Aytekin S, Bajraktari G, Ibrahimi P, Bytyci I, Ahmeti A, Batalli A, Elezi S, Henein M, Pavlyukova E, Tereshenkova E, Karpov R, Barbier P, Mirea O, Guglielmo M, Savioli G, Cefalu C, Maltagliati M, Tumasyan L, Adamyan K, Chilingaryan A, Tunyan L, Kowalik E, Klisiewicz A, Biernacka E, Hoffman P, Park C, Yi J, Cho J, Ihm S, Kim H, Cho E, Jeon H, Jung H, Youn H, Mcghie J, Menting M, Vletter W, Roos-Hesselink J, Geleijnse M, Van Der Zwaan H, Van Den Bosch A, Spethmann S, Baldenhofer G, Stangl V, Baumann G, Stangl K, Laule M, Dreger H, Knebel F, Erdei T, Edwards J, Braim D, Yousef Z, Fraser A, Keramida K, Kouris N, Kostopoulos V, Kostakou P, Petrogiannos C, Olympios C, Bajraktari G, Berisha G, Bytyci I, Ibrahimi P, Rexhepaj N, Henein M, Wdowiak-Okrojek K, Shim A, Wejner-Mik P, Szymczyk E, Michalski B, Kasprzak J, Lipiec P, Tarr A, Stoebe S, Pfeiffer D, Hagendorff A, Haykal M, Ryu S, Park J, Kim S, Choi J, Goh C, Byun Y, Choi J, Sonoko M, Onishi T, Fujimoto W, Yamada S, Taniguchi Y, Yasaka Y, Kawai H, Okura H, Sakamoto Y, Murata E, Kanai M, Kataoka T, Kimura T, Watanabe N, Kuriyama N, Nakama T, Furugen M, Sagara S, Koiwaya H, Ashikaga K, Matsuyama A, Shibata Y, Meimoun P, Abouth S, Martis S, Boulanger J, Elmkies F, Zemir H, Tzvetkov B, Luycx-Bore A, Clerc J, Galli E, Oger E, Guirette Y, Daudin M, Fournet M, Donal E, Galli E, Guirette Y, Mabo P, Donal E, Keramida K, Kouris N, Kostopoulos V, Psarrou G, Petrogiannos C, Hatzigiannis P, Olympios C, Igual Munoz B, Erdociain Perales M, Maceira Gonzalez Alicia A, Vazquez Sanchez A, Miro Palau V, Alonso Fernandez P, Donate Bertolin L, Estornell Erill J, Cervera A, Montero Argudo Anastasio A, Okura H, Koyama T, Maehama T, Imai K, Yamada R, Kume T, Neishi Y, Caballero Jimenez L, Garcia-Navarro M, Saura D, Oliva M, Gonzalez-Carrillo J, Espinosa M, Valdes M, De La Morena G, Venkateshvaran A, Sola S, Dash PK, Annappa C, Manouras A, Winter R, Brodin L, Govind SC, Laufer-Perl L, Topilsky Y, Stugaard M, Koriyama H, Katsuki K, Masuda K, Asanuma T, Takeda Y, Sakata Y, Nakatani S, Marta L, Abecasis J, Reis C, Dores H, Cafe H, Ribeiras R, Andrade M, Mendes M, Goebel B, Hamadanchi A, Schmidt-Winter C, Otto S, Jung C, Figulla H, Poerner T, Kim DH, Sun B, Jang J, Choi H, Song JM, Kang DH, Song JK, Zakhama L, Slama I, Boussabah E, Antit S, Herbegue B, Annabi M, Jalled A, Ben Ameur W, Thameur M, Ben Youssef S, O' Grady H, Gilmore M, Delassus P, Sturmberger T, Ebner C, Aichinger J, Tkalec W, Eder V, Nesser H, Caggegi AM, Scandura S, Capranzano P, Grasso C, Mangiafico S, Ronsivalle G, Dipasqua F, Arcidiacono A, Cannata S, Tamburino C, Chapman M, Henthorn R, Surikow S, Zoontjens J, Stocker B, Mclean T, Zeitz CJ, Fabregat Andres O, Estornell-Erill J, Ridocci-Soriano F, De La Espriella R, Albiach-Montanana C, Trejo-Velasco B, Perdomo-Londono D, Facila L, Morell S, Cortijo-Gimeno J, Kouris N, Keramida K, Kostopoulos V, Psarrou G, Kostakou P, Olympios C, Kuperstein R, Blechman I, Freimatk D, Arad M, Ochoa JP, Fernandez A, Vaisbuj F, Salmo F, Fava A, Casabe H, Guevara E, Fernandes A, Cateano F, Almeida I, Silva J, Trigo J, Botelho A, Sanches C, Venancio M, Goncalves L, Schnell F, Daudin M, Oger E, Bouillet P, Mabo P, Carre F, Donal E, Petrella L, Fabiani D, Paparoni S, De Remigis F, Tomassoni G, Prosperi F, Napoletano C, Marchel M, Serafin A, Kochanowski J, Steckiewicz R, Madej-Pilarczyk A, Filipiak K, Opolski G, Abid L, Ben Kahla S, Charfeddine S, Kammoun S, Monivas Palomero V, Mingo Santos S, Goirigoizarri Artaza J, Rodriguez Gonzalez E, Restrepo Cordoba A, Rivero Arribas B, Garcia Lunar I, Gomez Bueno M, Sayago Silva I, Segovia Cubero J, Zengin E, Radunski UK, Klusmeier M, Ojeda F, Rybczynski M, Barten M, Muellerleile K, Reichenspurner H, Blankenberg S, Sinning CR, Romano G, Licata P, Tuzzolino F, Clemenza F, Di Gesaro G, Hernandez Baravoglia C, Scardulla C, Pilato M, Hashimoto G, Suzuki M, Yoshikawa H, Otsuka T, Isekame Y, Iijima R, Hara H, Nakamura M, Sugi K, Melnikova M, Krestjyaninov M, Ruzov V, Magnino C, Omede' P, Avenatti E, Presutti D, Moretti C, Ravera A, Sabia L, Gaita F, Veglio F, Milan A, Magda S, Mincu R, Soare A, Mihai C, Florescu M, Mihalcea D, Cinteza M, Vinereanu D, Chatzistamatiou E, Mpampatseva Vagena I, Manakos K, Moustakas G, Konstantinidis D, Memo G, Mitsakis O, Kasakogias A, Syros P, Kallikazaros I, Petroni R, Acitelli A, Cicconetti M, Di Mauro M, Altorio S, Romano S, Petroni A, Penco M, Apostolovic S, Stanojevic D, Jankovic-Tomasevic R, Salinger-Martinovic S, Pavlovic M, Djordjevic-Radojkovic D, Tahirovic E, Dungen H, Jung IH, Byun YS, Goh CW, Kim BO, Rhee KJ, Lee DS, Kim MJ, Seo HS, Kim HY, Tsverava M, Tsverava D, Zaletova T, Shamsheva D, Parkhomenko O, Bogdanov A, Derbeneva S, Leotescu A, Tudor I, Gurghean A, Bruckner I, Plaskota K, Trojnarska O, Bartczak A, Grajek S, Sharma P, Sharma D, Garg S, Vazquez Lopez-Ibor J, Monivas Palomero V, Solano-Lopez J, Zegri Reiriz I, Dominguez Rodriguez F, Gonzalez Mirelis J, Mingo Santos S, Sayago I, Garcia Pavia P, Segovia Cubero J, Florescu M, Mihalcea D, Magda S, Radu E, Chirca A, Acasandrei A, Jinga D, Mincu R, Enescu O, Vinereanu D, Saura Espin D, Caballero Jimenez L, Oliva Sandoval M, Gonzalez Carrillo J, Garcia Navarro M, Espinosa Garcia M, Valdes Chavarri M, De La Morena Valenzuela G, Abul Fadl A, Mourad M, Campanale CM, Di Maria S, Mega S, Nusca A, Marullo F, Di Sciascio G, Pardo Gonzalez L, Delgado M, Ruiz M, Rodriguez S, Hidalgo F, Ortega R, Mesa D, Suarez De Lezo Cruz Conde J, Bengrid TM, Zhao Y, Henein M, Kenjaev S, Alavi A, Kenjaev M, Mendes L, Lima S, Dantas C, Melo I, Madeira V, Balao S, Alves H, Baptista E, Mendes P, Santos J, Scali M, Mandoli G, Simioniuc A, Massaro F, Di Bello V, Marzilli M, Dini F, Cifra B, Dragulescu A, Friedberg M, Mertens L, Scali M, Bayramoglu A, Tasolar H, Otlu Y, Hidayet S, Kurt F, Dogan A, Pekdemir H, Stefani L, Galanti G, De Luca A, Toncelli L, Pedrizzetti G, Gopal AS, Saha S, Toole R, Kiotsekoglou A, Cao J, Reichek N, Ho SJ, Hung SC, Chang FY, Liao JN, Niu DM, Yu WC, Nemes A, Kalapos A, Domsik P, Forster T, Siarkos M, Sammut E, Lee L, Jackson T, Carr-White G, Rajani R, Kapetanakis S, Jarvinen V, Sipola P, Madeo A, Piras P, Evangelista A, Giura G, Dominici T, Nardinocchi P, Varano V, Chialastri C, Puddu P, Torromeo C, Sanchis Ruiz L, Montserrat S, Obach V, Cervera A, Bijnens B, Sitges M, Charisopoulou D, Banner NR, Rahman-Haley S, Imperadore F, Del Greco M, Jermendy A, Horcsik D, Horvath T, Celeng C, Nagy E, Bartykowszki A, Tarnoki D, Merkely B, Maurovich-Horvat P, Jermendy G, Whitaker J, Demir O, Walton J, Wragg A, Alfakih K, Karolyi M, Szilveszter B, Raaijmakers R, Giepmans W, Horvath T, Merkely B, Maurovich-Horvat P, Koulaouzidis G, Charisopoulou D, Mcarthur T, Jenkins P, Henein M, Silva T, Ramos R, Oliveira M, Marques H, Cunha P, Silva M, Barbosa C, Sofia A, Pimenta R, Ferreira R, Al-Mallah M, Alsaileek A. Poster session 5: Friday 5 December 2014, 14:00-18:00 * Location: Poster area. Eur Heart J Cardiovasc Imaging 2014. [DOI: 10.1093/ehjci/jeu257] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Goirigolzarri Artaza J, Gallego Delgado M, Jaimes Castellanos C, Cavero Gibanel M, Pastrana Ledesma M, Alonso Pulpon L, Gonzalez Mirelis J, Al Ansi RZ, Sokolovic S, Cerin G, Szychta W, Popa BA, Botezatu D, Benea D, Manganiello S, Corlan A, Jabour A, Igual Munoz B, Osaca Asensi J, Andres La Huerta A, Maceira Gonzalez A, Estornell Erill J, Cano Perez O, Sancho-Tello M, Alonso Fernandez P, Sepulveda Sanchez P, Montero Argudo A, Palombo C, Morizzo C, Baluci M, Kozakova M, Panajotu A, Karady J, Szeplaki G, Horvath T, Tarnoki D, Jermendy A, Geller L, Merkely B, Maurovich-Horvat P, Moustafa S, Mookadam F, Youssef M, Zuhairy H, Connelly M, Prieur T, Alvarez N, Ashikhmin Y, Drapkina O, Boutsikou M, Demerouti E, Leontiadis E, Petrou E, Karatasakis G, Kozakova M, Morizzo C, Bianchi V, Marchi B, Federico G, Palombo C, Chatzistamatiou E, Moustakas G, Memo G, Konstantinidis D, Mpampatzeva Vagena I, Manakos K, Traxanas K, Vergi N, Feretou A, Kallikazaros I, Goto M, Uejima T, Itatani K, Pedrizzetti G, Mada R, Daraban A, Duchenne J, Voigt J, Chiu DYY, Green D, Johnstone L, Sinha S, Kalra P, Abidin N, Sikora-Frac M, Zaborska B, Maciejewski P, Bednarz B, Budaj A, Nemes A, Sasi V, Gavaller H, Kalapos A, Domsik P, Katona A, Szucsborus T, Ungi T, Forster T, Ungi I, Pluchinotta F, Arcidiacono C, Saracino A, Carminati M, Bussadori C, Dahlslett T, Karlsen S, Grenne B, Sjoli B, Bendz B, Skulstad H, Smiseth O, Edvardsen T, Brunvand H, Vereckei A, Szelenyi Z, Szenasi G, Santoro C, Galderisi M, Niglio T, Santoro M, Stabile E, Rapacciuolo A, Spinelli L, De Simone G, Esposito G, Trimarco B, Hubert S, Jacquier A, Fromonot J, Resseguier C, Tessier A, Guieu R, Renard S, Haentjiens J, Lavoute C, Habib G, Menting ME, Koopman L, Mcghie J, Rebel B, Gnanam D, Helbing W, Van Den Bosch A, Roos-Hesselink J, Shiino K, Yamada A, Sugimoto K, Takada K, Takakuwa Y, Miyagi M, Iwase M, Ozaki Y, Hayashi T, Itatani K, Inuzuka R, Shindo T, Hirata Y, Shimizu N, Miyaji K, Henri C, Dulgheru R, Magne J, Kou S, Davin L, Nchimi A, Oury C, Pierard L, Lancellotti P, Kovalyova O, Honchar O, Tengku W, Ketaren A, Mingo Santos S, Monivas Palomero V, Restrepo Cordoba A, Rodriguez Gonzalez E, Goirigolzarri Artaza J, Sayago Silva I, Garcia Lunar I, Mitroi C, Cavero Gibanel M, Segovia Cubero J, Ryu S, Park J, Kim S, Choi J, Goh C, Byun Y, Choi J, Westholm C, Johnson J, Jernberg T, Winter R, Rio P, Moura Branco L, Galrinho A, Pinto Teixeira P, Viveiros Monteiro A, Portugal G, Pereira-Da-Silva T, Afonso Nogueira M, Abreu J, Cruz Ferreira R, Mazzone A, Botto N, Paradossi U, Chabane A, Francini M, Cerone E, Baroni M, Maffei S, Berti S, Ghattas A, Shantsila E, Griffiths H, Lip G, Galli E, Guirette Y, Daudin M, Auffret V, Mabo P, Donal E, Fabiani I, Conte L, Scatena C, Barletta V, Pratali S, De Martino A, Bortolotti U, Naccarato A, Di Bello V, Falanga G, Alati E, Di Giannuario G, Zito C, Cusma' Piccione M, Carerj S, Oreto G, Dattilo G, Alfieri O, La Canna G, Generati G, Bandera F, Pellegrino M, Alfonzetti E, Labate V, Guazzi M, Cengiz B, Sahin ST, Yurdakul S, Kahraman S, Bozkurt A, Aytekin S, Borges IP, Peixoto E, Peixoto R, Peixoto R, Marcolla V, Venkateshvaran A, Sola S, Dash PK, Thapa P, Manouras A, Winter R, Brodin L, Govind SC, Mizariene V, Verseckaite R, Bieseviciene M, Karaliute R, Jonkaitiene R, Vaskelyte J, Arzanauskiene R, Janenaite J, Jurkevicius R, Rosner S, Orban M, Nadjiri J, Lesevic H, Hadamitzky M, Sonne C, Manganaro R, Carerj S, Cusma-Piccione M, Caprino A, Boretti I, Todaro M, Falanga G, Oreto L, D'angelo M, Zito C, Le Tourneau T, Cueff C, Richardson M, Hossein-Foucher C, Fayad G, Roussel J, Trochu J, Vincentelli A, Cavalli G, Muraru D, Miglioranza M, Addetia K, Veronesi F, Cucchini U, Mihaila S, Tadic M, Lang R, Badano L, Polizzi V, Pino P, Luzi G, Bellavia D, Fiorilli R, Chialastri C, Madeo A, Malouf J, Buffa V, Musumeci F, Gripari P, Tamborini G, Bottari V, Maffessanti F, Carminati C, Muratori M, Vignati C, Bartorelli A, Alamanni F, Pepi M, Polymeros S, Dimopoulos A, Spargias K, Karatasakis G, Athanasopoulos G, Pavlides G, Dagres N, Vavouranakis E, Stefanadis C, Cokkinos D, Pradel S, Mohty D, Magne J, Darodes N, Lavergne D, Damy T, Beaufort C, Aboyans V, Jaccard A, Mzoughi K, Zairi I, Jabeur M, Ben Moussa F, Ben Chaabene A, Kamoun S, Mrabet K, Fennira S, Zargouni A, Kraiem S, Jovanova S, Arnaudova-Dezjulovic F, Correia CE, Cruz I, Marques N, Fernandes M, Bento D, Moreira D, Lopes L, Azevedo O, Keramida K, Kouris N, Kostopoulos V, Psarrou G, Giannaris V, Olympios C, Marketou M, Parthenakis F, Kalyva N, Pontikoglou C, Maragkoudakis S, Zacharis E, Patrianakos A, Roufas K, Papadaki H, Vardas P, Dominguez Rodriguez F, Monivas Palomero V, Mingo Santos S, Arribas Rivero B, Cuenca Parra S, Zegri Reiriz I, Vazquez Lopez-Ibor J, Garcia-Pavia P, Szulik M, Streb W, Wozniak A, Lenarczyk R, Sliwinska A, Kalarus Z, Kukulski T, Nemes A, Domsik P, Kalapos A, Forster T, Serra W, Lumetti F, Mozzani F, Del Sante G, Ariani A, Corros C, Colunga S, Garcia-Campos A, Diaz E, Martin M, Rodriguez-Suarez M, Leon V, Fidalgo A, Moris C, De La Hera J, Kylmala MM, Rosengard-Barlund M, Groop PH, Lommi J, Bruin De- Bon H, Bilt Van Der I, Wilde A, Brink Van Den R, Teske A, Rinkel G, Bouma B, Teixeira R, Monteiro R, Garcia J, Silva A, Graca M, Baptista R, Ribeiro M, Cardim N, Goncalves L, Duszanska A, Skoczylas I, Kukulski T, Polonski L, Kalarus Z, Choi JH, Park J, Ahn J, Lee J, Ryu S, Ahn J, Kim D, Lee H, Przewlocka-Kosmala M, Mlynarczyk J, Rojek A, Mysiak A, Kosmala W, Pellissier A, Larochelle E, Krsticevic L, Baron E, Le V, Roy A, Deragon A, Cote M, Garcia D, Tournoux F, Yiangou K, Azina C, Yiangou A, Zitti M, Ioannides M, Ricci F, Dipace G, Aquilani R, Radico F, Cicchitti V, Bianco F, Miniero E, Petrini F, De Caterina R, Gallina S, Jardim Prista Monteiro R, Teixeira R, Garcia J, Baptista R, Ribeiro M, Cardim N, Goncalves L, Chung H, Kim J, Joung B, Uhm J, Pak H, Lee M, Lee K, Ragab A, Abdelwahab A, Yazeed Y, El Naggar W, Spahiu K, Spahiu E, Doko A, Liesting C, Brugts J, Kofflard M, Kitzen J, Boersma E, Levin MD, Coppola C, Piscopo G, Rea D, Maurea C, Caronna A, Capasso I, Maurea N, Azevedo O, Tadeu I, Lourenco M, Portugues J, Pereira V, Lourenco A, Nesukay E, Kovalenko V, Cherniuk S, Danylenko O, Nemes A, Domsik P, Kalapos A, Lengyel C, Varkonyi T, Orosz A, Forster T, Castro M, Abecasis J, Dores H, Madeira S, Horta E, Ribeiras R, Canada M, Andrade M, Mendes M, Morosin M, Piazza R, Leonelli V, Leiballi E, Pecoraro R, Cinello M, Dell' Angela L, Cassin M, Sinagra G, Nicolosi G, Wierzbowska-Drabik K, Hamala P, Kasprzak J, O'driscoll J, Rossato C, Gargallo-Fernandez P, Araco M, Sharma S, Sharma R, Jakus N, Baricevic Z, Ljubas Macek J, Skoric B, Skorak I, Velagic V, Separovic Hanzevacki J, Milicic D, Cikes M, Deljanin Ilic M, Ilic S, Kocic G, Pavlovic R, Stoickov V, Ilic V, Nikolic L, Generati G, Bandera F, Pellegrino M, Alfonzetti E, Labate V, Guazzi M, Labate V, Bandera F, Generati G, Pellegrino M, Donghi V, Alfonzetti E, Guazzi M, Zakarkaite D, Kramena R, Aidietiene S, Janusauskas V, Rucinskas K, Samalavicius R, Norkiene I, Speciali G, Aidietis A, Kemaloglu Oz T, Ozpamuk Karadeniz F, Akyuz S, Unal Dayi S, Esen Zencirci A, Atasoy I, Osken A, Eren M, Fazendas PR, Caldeira D, Stuart B, Cruz I, Rocha Lopes L, Almeida AR, Sousa P, Joao I, Cotrim C, Pereira H, Fazendas PR, Caldeira D, Stuart B, Cruz I, Rocha Lopes L, Almeida AR, Joao I, Cotrim C, Pereira H, Sinem Cakal S, Elif Eroglu E, Baydar O, Beytullah Cakal B, Mehmet Vefik Yazicioglu M, Mustafa Bulut M, Cihan Dundar C, Kursat Tigen K, Birol Ozkan B, Ali Metin Esen A, Yagasaki H, Kawasaki M, Tanaka R, Minatoguchi S, Houle H, Warita S, Ono K, Noda T, Watanabe S, Minatoguchi S, Cho EJ, Park SJ, Lim HJ, Chang SA, Lee SC, Park SW, Cho EJ, Park SJ, Lim HJ, Chang SA, Lee SC, Park SW, Mornos C, Cozma D, Ionac A, Mornos A, Popescu I, Ionescu G, Pescariu S, Melzer L, Faeh-Gunz A, Seifert B, Attenhofer Jost CH, Storve S, Haugen B, Dalen H, Grue J, Samstad S, Torp H, Ferrarotti L, Maggi E, Piccinino C, Sola D, Pastore F, Marino P, Ranjbar S, Karvandi M, Hassantash S, Karvandi M, Ranjbar S, Tierens S, Remory I, Bala G, Gillis K, Hernot S, Droogmans S, Cosyns B, Lahoutte T, Tran N, Poelaert J, Al-Mallah M, Alsaileek A, Nour K, Celeng C, Horvath T, Kolossvary M, Karolyi M, Panajotu A, Kitslaar P, Merkely B, Maurovich Horvat P, Aguiar Rosa S, Ramos R, Marques H, Portugal G, Pereira Da Silva T, Rio P, Afonso Nogueira M, Viveiros Monteiro A, Figueiredo L, Cruz Ferreira R. Poster session 6. Eur Heart J Cardiovasc Imaging 2014; 15:ii235-ii264. [PMCID: PMC4453635 DOI: 10.1093/ehjci/jeu271] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/13/2023] Open
|
32
|
Tong L, Huang C, Ramalli A, Tortoli P, Luo J, D'hooge J, Tzemos N, Mordi I, Bishay T, Bishay T, Negishi T, Hristova K, Kurosawa K, Bansal M, Thavendiranathan P, Yuda S, Popescu B, Vinereanu D, Penicka M, Marwick T, Hamed W, Kamel M, Yaseen R, El-Barbary H, Nemes A, Kis O, Gavaller H, Kanyo E, Forster T, Angelis A, Vlachopoulos C, Ioakimidis N, Felekos I, Chrysohoou C, Aznaouridis K, Abdelrasoul M, Terentes D, Ageli K, Stefanadis C, Kurnicka K, Domienik-Karlowicz J, Lichodziejewska B, Goliszek S, Grudzka K, Krupa M, Dzikowska-Diduch O, Ciurzynski M, Pruszczyk P, Gual Capllonch F, Lopez Ayerbe J, Teis A, Ferrer E, Vallejo N, Junca G, Pla R, Bayes-Genis A, Schwaiger J, Knight D, Gallimore A, Schreiber B, Handler C, Coghlan J, Bruno RM, Giardini G, Malacrida S, Catuzzo B, Armenia S, Brustia R, Ghiadoni L, Cauchy E, Pratali L, Kim K, Lee K, Cho J, Yoon H, Ahn Y, Jeong M, Cho J, Park J, Cho S, Nastase O, Enache R, Mateescu A, Botezatu D, Popescu B, Ginghina C, Gu H, Sinha M, Simpson J, Chowienczyk P, Fazlinezhad A, Tashakori Behesthi A, Homaei F, Mostafavi H, Hosseini G, Bakaeiyan M, Boutsikou M, Petrou E, Dimopoulos A, Dritsas A, Leontiadis E, Karatasakis G, Sahin ST, Yurdakul S, Yilmaz N, Cengiz B, Cagatay Y, Aytekin S, Yavuz S, Karlsen S, Dahlslett T, Grenne B, Sjoli B, Smiseth O, Edvardsen T, Brunvand H, Nasr G, Nasr A, Eleraki A, Elrefai S, Mordi I, Sonecki P, Tzemos N, Gustafsson U, Naar J, Stahlberg M, Cerne A, Capotosto L, Rosato E, D'angeli I, Azzano A, Truscelli G, De Maio M, Salsano F, Terzano C, Mangieri E, Vitarelli A, Renard S, Najih H, Mancini J, Jacquier A, Haentjens J, Gaubert J, Habib G, Caminiti G, D'antoni V, D'antoni V, Cardaci V, Cardaci V, Conti V, Conti V, Volterrani M, Volterrani M, Ahn J, Kim D, Lee H, Iliuta L, Lo Iudice F, Esposito R, Lembo M, Santoro C, Ballo P, Mondillo S, De Simone G, Galderisi M, Hwang Y, Kim J, Kim J, Moon K, Yoo K, Kim C, Tagliamonte E, Rigo F, Cirillo T, Caruso A, Astarita C, Cice G, Quaranta G, Romano C, Capuano N, Calabro' R, Zagatina A, Zhuravskaya N, Guseva O, Huttin O, Benichou M, Voilliot D, Venner C, Micard E, Girerd N, Sadoul N, Moulin F, Juilliere Y, Selton-Suty C, Baron T, Christersson C, Johansson K, Flachskampf F, Lee S, Lee J, Hur S, Park J, Yun J, Song S, Kim W, Ko J, Nyktari E, Bilal S, Ali S, Izgi C, Prasad S, Aly M, Kleijn S, Kandil H, Kamp O, Beladan C, Calin A, Rosca M, Craciun A, Gurzun M, Calin C, Enache R, Mateescu A, Ginghina C, Popescu B, Mornos C, Mornos A, Ionac A, Cozma D, Crisan S, Popescu I, Ionescu G, Petrescu L, Camacho S, Gamaza Chulian S, Carmona R, Diaz E, Giraldez A, Gutierrez A, Toro R, Benezet J, Antonini-Canterin F, Vriz O, La Carrubba S, Poli S, Leiballi E, Zito C, Careri S, Caruso R, Pellegrinet M, Nicolosi G, Kong W, Kyu K, Wong R, Tay E, Yip J, Yeo T, Poh K, Correia M, Delgado A, Marmelo B, Correia E, Abreu L, Cabral C, Gama P, Santos O, Rahman M, Borges IP, Peixoto E, Peixoto R, Peixoto R, Marcolla V, Okura H, Kanai M, Murata E, Kataoka T, Stoebe S, Tarr A, Pfeiffer D, Hagendorff A, Generati G, Bandera F, Pellegrino M, Alfonzetti E, Labate V, Guazzi M, Kuznetsov V, Yaroslavskaya E, Pushkarev G, Krinochkin D, Zyrianov I, Carigi S, Baldazzi F, Bologna F, Amati S, Venturi P, Grosseto D, Biagetti C, Fabbri E, Arlotti M, Piovaccari G, Rahbi H, Bin Abdulhaq A, Tleyjeh I, Santoro C, Galderisi M, Costantino M, Tarsia G, Innelli P, Dores E, Esposito G, Matera A, De Simone G, Trimarco B, Capotosto L, Azzano A, Mukred K, Ashurov R, Tanzilli G, Mangieri E, Vitarelli A, Merlo M, Gigli M, Stolfo D, Pinamonti B, Antonini Canterin F, Muca M, D'angelo G, Scapol S, Di Nucci M, Sinagra G, Behaghel A, Feneon D, Fournet M, Thebault C, Martins R, Mabo P, Leclercq C, Daubert C, Donal E, Davinder Pal S, Prakash Chand N, Sanjeev A, Rajeev M, Ankur D, Ram Gopal S, Mzoughi K, Zairi I, Jabeur M, Ben Moussa F, Ben Chaabene A, Kamoun S, Mrabet K, Fennira S, Zargouni A, Kraiem S, Demkina A, Hashieva F, Krylova N, Kovalevskaya E, Potehkina N, Zaroui A, Ben Said R, Smaali S, Rekik B, Ben Hlima M, Mizouni H, Mechmeche R, Mourali M, Malhotra A, Sheikh N, Dhutia H, Siva A, Narain R, Merghani A, Millar L, Walker M, Sharma S, Papadakis M, Siam-Tsieu V, Mansencal N, Arslan M, Deblaise J, Dubourg O, Zaroui A, Rekik B, Ben Said R, Boudiche S, Larbi N, Tababi N, Hannachi S, Mechmeche R, Mourali M, Mechmeche R, Zaroui A, Chalbia T, Ben Halima M, Rekik B, Boussada R, Mourali M, Lipari P, Bonapace S, Valbusa F, Rossi A, Zenari L, Lanzoni L, Targher G, Canali G, Molon G, Barbieri E, Novo G, Giambanco S, Sutera M, Bonomo V, Giambanco F, Rotolo A, Evola S, Assennato P, Novo S, Budnik M, Piatkowski R, Kochanowski J, Opolski G, Chatzistamatiou E, Mpampatseva Vagena I, Manakos K, Moustakas G, Konstantinidis D, Memo G, Mitsakis O, Kasakogias A, Syros P, Kallikazaros I, Marketou M, Parthenakis F, Kalyva N, Pontikoglou C, Maragkoudakis S, Zacharis E, Patrianakos A, Maragoudakis F, Papadaki H, Vardas P, Rodrigues A, Perandini L, Souza T, Sa-Pinto A, Borba E, Arruda A, Furtado M, Carvalho F, Bonfa E, Andrade J, Hlubocka Z, Malinova V, Palecek T, Danzig V, Kuchynka P, Dostalova G, Zeman J, Linhart A, Chatzistamatiou E, Konstantinidis D, Memo G, Mpampatzeva Vagena I, Moustakas G, Manakos K, Trachanas K, Vergi N, Feretou A, Kallikazaros I, Corut H, Sade L, Ozin B, Atar I, Turgay O, Muderrisoglu H, Ledakowicz-Polak A, Polak L, Krauza G, Zielinska M, Szulik M, Streb W, Wozniak A, Lenarczyk R, Sliwinska A, Kalarus Z, Kukulski T, Nogueira M, Branco L, Agapito A, Galrinho A, Borba A, Teixeira P, Monteiro A, Ramos R, Cacela D, Cruz Ferreira R, Guala A, Camporeale C, Tosello F, Canuto C, Ridolfi L, Chatzistamatiou E, Moustakas G, Memo G, Konstantinidis D, Mpampatzeva Vagena I, Manakos K, Traxanas K, Vergi N, Feretou A, Kallikazaros I, Hristova K, Marinov R, Stamenov G, Mihova M, Persenska S, Racheva A, Plaskota K, Trojnarska O, Bartczak A, Grajek S, Ramush Bejiqi R, Retkoceri R, Bejiqi H, Beha A, Surdulli S, Dreyfus J, Durand-Viel G, Cimadevilla C, Brochet E, Vahanian A, Messika-Zeitoun D, Jin C, Fang F, Meng F, Kam K, Sun J, Tsui G, Wong K, Wan S, Yu C, Lee A, Cho IJ, Chung H, Heo R, Ha S, Hong G, Shim C, Chang H, Ha J, Chung N, Moral S, Gruosso D, Galuppo V, Teixido G, Rodriguez-Palomares J, Gutierrez L, Evangelista A, Moral S, Gruosso D, Galuppo V, Teixido G, Rodriguez-Palomares J, Gutierrez L, Evangelista A, Moral S, Gruosso D, Galuppo V, Teixido G, Rodriguez-Palomares J, Gutierrez L, Evangelista A, Alexopoulos A, Dawson D, Nihoyannopoulos P, Zainal Abidin HA, Ismail J, Arshad K, Ibrahim Z, Lim C, Abd Rahman E, Kasim S, Peteiro J, Barrio A, Escudero A, Bouzas-Mosquera A, Yanez J, Martinez D, Castro-Beiras A, Scali M, Simioniuc A, Mandoli G, Lombardo A, Massaro F, Di Bello V, Marzilli M, Dini F, Adachi H, Tomono J, Oshima S, Merchan Ortega G, Bravo Bustos D, Lazaro Garcia R, Sanchez Espino A, Macancela Quinones J, Ikuta I, Ruiz Lopez M, Valencia Serrano F, Bonaque Gonzalez J, Gomez Recio M, Romano G, D'ancona G, Pilato G, Di Gesaro G, Clemenza F, Raffa G, Scardulla C, Sciacca S, Lancellotti P, Pilato M, Addetia K, Takeuchi M, Maffessanti F, Weinert L, Hamilton J, Mor-Avi V, Lang R, Sugano A, Seo Y, Watabe H, Kakefuda Y, Aihara H, Nishina H, Ishizu T, Fumikura Y, Noguchi Y, Aonuma K, Luo X, Fang F, Lee A, Shang Q, Yu C, Sammut EC, Chabinok R, Jackson T, Siarkos M, Lee L, Carr-White G, Rajani R, Kapetanakis S, Byrne D, Walsh J, Ellis L, Mckiernan S, Norris S, King G, Murphy R, Hristova K, Katova T, Simova I, Kostova V, Shuie I, Ferferieva V, Bogdanova V, Castelon X, Nemes A, Sasi V, Domsik P, Kalapos A, Lengyel C, Orosz A, Forster T, Grapsa J, Demir O, Dawson D, Sharma R, Senior R, Nihoyannopoulos P, Pilichowska E, Zaborska B, Baran J, Stec S, Kulakowski P, Budaj A, Kosmala W, Kaye G, Saito M, Negishi K, Marwick T, Maceira Gonzalez AM, Ripoll C, Cosin-Sales J, Igual B, Salazar J, Belloch V, Dulai RS, Taylor A, Gupta S. Poster session 1: Wednesday 3 December 2014, 09:00-16:00 * Location: Poster area. Eur Heart J Cardiovasc Imaging 2014; 15:ii25-ii51. [DOI: 10.1093/ehjci/jeu248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 09/02/2023] Open
|
33
|
Hamuryudan V, Seyahi E, Melikoglu M, Ugurlu S, Hatemi G, Yurdakul S, Yazici H. AB0602 Anti-TNF Treatment for Refractory Vascular Involvement of BehÇEt's Syndrome: A Report of 16 Patients. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1805] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
34
|
Abdovic E, Abdovic S, Hristova K, Hristova K, Katova T, Katova T, Gocheva N, Gocheva N, Pavlova M, Pavlova M, Gurzun MM, Ionescu A, Canpolat U, Yorgun H, Sunman H, Sahiner L, Kaya E, Ozer N, Tokgozoglu L, Kabakci G, Aytemir K, Oto A, Gonella A, D'ascenzo F, Casasso F, Conte E, Margaria F, Grosso Marra W, Frea S, Morello M, Bobbio M, Gaita F, Seo H, Lee S, Lee J, Yoon Y, Park E, Kim H, Park S, Lee H, Kim Y, Sohn D, Nemes A, Domsik P, Kalapos A, Orosz A, Lengyel C, Forster T, Enache R, Muraru D, Popescu B, Calin A, Nastase O, Botezatu D, Purcarea F, Rosca M, Beladan C, Ginghina C, Canpolat U, Aytemir K, Ozer N, Yorgun H, Sahiner L, Kaya E, Oto A, Muraru D, Piasentini E, Mihaila S, Padayattil Jose' S, Peluso D, Ucci L, Naso P, Puma L, Iliceto S, Badano L, Cikes M, Jakus N, Sutherland G, Haemers P, D'hooge J, Claus P, Yurdakul S, Oner F, Direskeneli H, Sahin T, Cengiz B, Ercan G, Bozkurt A, Aytekin S, Osa Saez AM, Rodriguez-Serrano M, Lopez-Vilella R, Buendia-Fuentes F, Domingo-Valero D, Quesada-Carmona A, Miro-Palau V, Arnau-Vives M, Palencia-Perez M, Rueda-Soriano J, Lipczynska M, Piotr Szymanski P, Anna Klisiewicz A, Lukasz Mazurkiewicz L, Piotr Hoffman P, Kim K, Cho S, Ahn Y, Jeong M, Cho J, Park J, Chinali M, Franceschini A, Matteucci M, Doyon A, Esposito C, Del Pasqua A, Rinelli G, Schaefer F, Kowalik E, Klisiewicz A, Rybicka J, Szymanski P, Biernacka E, Hoffman P, Lee S, Kim W, Yun H, Jung L, Kim E, Ko J, Ruddox V, Norum I, Edvardsen T, Baekkevar M, Otterstad J, Erdei T, Edwards J, Braim D, Yousef Z, Fraser A, Melcher A, Reiner B, Hansen A, Strandberg L, Caidahl K, Wellnhofer E, Kriatselis C, Gerd-Li H, Furundzija V, Thnabalasingam U, Fleck E, Graefe M, Park Y, Moon J, Ahn T, Baydar O, Kadriye Kilickesmez K, Ugur Coskun U, Polat Canbolat P, Veysel Oktay V, Umit Yasar Sinan U, Okay Abaci O, Cuneyt Kocas C, Sinan Uner S, Serdar Kucukoglu S, Ferferieva V, Claus P, Rademakers F, D'hooge J, Le TT, Wong P, Tee N, Huang F, Tan R, Altman M, Logeart D, Bergerot C, Gellen B, Pare C, Gerard S, Sirol M, Vicaut E, Mercadier J, Derumeaux GA, Park TH, Park JI, Shin SW, Yun SH, Lee JE, Makavos G, Kouris N, Keramida K, Dagre A, Ntarladimas I, Kostopoulos V, Damaskos D, Olympios C, Leong D, Piers S, Hoogslag G, Hoke U, Thijssen J, Ajmone Marsan N, Schalij M, Bax J, Zeppenfeld K, Delgado V, Rio P, Branco L, Galrinho A, Cacela D, Abreu J, Timoteo A, Teixeira P, Pereira-Da-Silva T, Selas M, Cruz Ferreira R, Popa BA, Zamfir L, Novelli E, Lanzillo G, Karazanishvili L, Musica G, Stelian E, Benea D, Diena M, Cerin G, Fusini L, Mirea O, Tamborini G, Muratori M, Gripari P, Ghulam Ali S, Cefalu' C, Maffessanti F, Andreini D, Pepi M, Mamdoo F, Goncalves A, Peters F, Matioda H, Govender S, Dos Santos C, Essop M, Kuznetsov VA, Yaroslavskaya EI, Pushkarev GS, Krinochkin DV, Kolunin GV, Bennadji A, Hascoet S, Dulac Y, Hadeed K, Peyre M, Ricco L, Clement L, Acar P, Ding W, Zhao Y, Lindqvist P, Nilson J, Winter R, Holmgren A, Ruck A, Henein M, Illatopa V, Cordova F, Espinoza D, Ortega J, Cavalcante J, Patel M, Katz W, Schindler J, Crock F, Khanna M, Khandhar S, Tsuruta H, Kohsaka S, Murata M, Yasuda R, Tokuda H, Kawamura A, Maekawa Y, Hayashida K, Fukuda K, Le Tourneau T, Kyndt F, Lecointe S, Duval D, Rimbert A, Merot J, Trochu J, Probst V, Le Marec H, Schott J, Veronesi F, Addetia K, Corsi C, Lamberti C, Lang R, Mor-Avi V, Gjerdalen GF, Hisdal J, Solberg E, Andersen T, Radunovic Z, Steine K, Maffessanti F, Gripari P, Tamborini G, Muratori M, Fusini L, Ferrari C, Caiani E, Alamanni F, Bartorelli A, Pepi M, D'ascenzi F, Cameli M, Iadanza A, Lisi M, Reccia R, Curci V, Sinicropi G, Henein M, Pierli C, Mondillo S, Rekhraj S, Hoole S, Mcnab D, Densem C, Boyd J, Parker K, Shapiro L, Rana B, Kotrc M, Vandendriessche T, Bartunek J, Claeys M, Vanderheyden M, Paelinck B, De Bock D, De Maeyer C, Vrints C, Penicka M, Silveira C, Albuquerque E, Lamprea D, Larangeiras V, Moreira C, Victor Filho M, Alencar B, Silveira A, Castillo J, Zambon E, Iorio A, Carriere C, Pantano A, Barbati G, Bobbo M, Abate E, Pinamonti B, Di Lenarda A, Sinagra G, Salemi VMC, Tavares L, Ferreira Filho J, Oliveira A, Pessoa F, Ramires F, Fernandes F, Mady C, Cavarretta E, Lotrionte M, Abbate A, Mezzaroma E, De Marco E, Peruzzi M, Loperfido F, Biondi-Zoccai G, Frati G, Palazzoni G, Park TH, Lee JE, Lee DH, Park JS, Park K, Kim MH, Kim YD, Van 'T Sant J, Gathier W, Leenders G, Meine M, Doevendans P, Cramer M, Poyhonen P, Kivisto S, Holmstrom M, Hanninen H, Schnell F, Betancur J, Daudin M, Simon A, Carre F, Tavard F, Hernandez A, Garreau M, Donal E, Calore C, Muraru D, Badano L, Melacini P, Mihaila S, Denas G, Naso P, Casablanca S, Santi F, Iliceto S, Aggeli C, Venieri E, Felekos I, Anastasakis A, Ritsatos K, Kakiouzi V, Kastellanos S, Cutajar I, Stefanadis C, Palecek T, Honzikova J, Poupetova H, Vlaskova H, Kuchynka P, Linhart A, Elmasry O, Mohamed M, Elguindy W, Bishara P, Garcia-Gonzalez P, Cozar-Santiago P, Bochard-Villanueva B, Fabregat-Andres O, Cubillos-Arango A, Valle-Munoz A, Ferrer-Rebolleda J, Paya-Serrano R, Estornell-Erill J, Ridocci-Soriano F, Jensen M, Havndrup O, Christiansen M, Andersen P, Axelsson A, Kober L, Bundgaard H, Karapinar H, Kaya A, Uysal E, Guven A, Kucukdurmaz Z, Oflaz M, Deveci K, Sancakdar E, Gul I, Yilmaz A, Tigen MK, Karaahmet T, Dundar C, Yalcinsoy M, Tasar O, Bulut M, Takir M, Akkaya E, Jedrzejewska I, Braksator W, Krol W, Swiatowiec A, Dluzniewski M, Lipari P, Bonapace S, Zenari L, Valbusa F, Rossi A, Lanzoni L, Molon G, Canali G, Campopiano E, Barbieri E, Rueda Calle E, Alfaro Rubio F, Gomez Gonzalez J, Gonzalez Santos P, Cameli M, Lisi M, Focardi M, D'ascenzi F, Solari M, Galderisi M, Mondillo S, Pratali L, Bruno RM, Corciu A, Comassi M, Passera M, Gastaldelli A, Mrakic-Sposta S, Vezzoli A, Picano E, Perry R, Penhall A, De Pasquale C, Selvanayagam J, Joseph M, Simova II, Katova TM, Kostova V, Hristova K, Lalov I, D'ascenzi F, Pelliccia A, Natali B, Cameli M, Alvino F, Zorzi A, Corrado D, Bonifazi M, Mondillo S, Rees E, Rakebrandt F, Rees D, Halcox J, Fraser A, O'driscoll J, Lau N, Perez-Lopez M, Sharma R, Lichodziejewska B, Goliszek S, Kurnicka K, Kostrubiec M, Dzikowska Diduch O, Krupa M, Grudzka K, Ciurzynski M, Palczewski P, Pruszczyk P, Gheorghe L, Castillo Ortiz J, Del Pozo Contreras R, Calle Perez G, Sancho Jaldon M, Cabeza Lainez P, Vazquez Garcia R, Fernandez Garcia P, Chueca Gonzalez E, Arana Granados R, Zhao X, Xu X, Bai Y, Qin Y, Leren I, Hasselberg N, Saberniak J, Leren T, Edvardsen T, Haugaa K, Daraban AM, Sutherland G, Claus P, Werner B, Gewillig M, Voigt J, Santoro A, Ierano P, De Stefano F, Esposito R, De Palma D, Ippolito R, Tufano A, Galderisi M, Costa R, Fischer C, Rodrigues A, Monaco C, Lira Filho E, Vieira M, Cordovil A, Oliveira E, Mohry S, Gaudron P, Niemann M, Herrmann S, Strotmann J, Beer M, Hu K, Bijnens B, Ertl G, Weidemann F, Baktir A, Sarli B, Cicek M, Karakas M, Saglam H, Arinc H, Akil M, Kaya H, Ertas F, Bilik M, Yildiz A, Oylumlu M, Acet H, Aydin M, Yuksel M, Alan S, O'driscoll J, Gravina A, Di Fino S, Thompson M, Karthigelasingham A, Ray K, Sharma R, De Chiara B, Russo C, Alloni M, Belli O, Spano' F, Botta L, Palmieri B, Martinelli L, Giannattasio C, Moreo A, Mateescu A, La Carrubba S, Vriz O, Di Bello V, Carerj S, Zito C, Ginghina C, Popescu B, Nicolosi G, Antonini-Canterin F, Malev E, Omelchenko M, Vasina L, Luneva E, Zemtsovsky E, Cikes M, Velagic V, Gasparovic H, Kopjar T, Colak Z, Hlupic L, Biocina B, Milicic D, Tomaszewski A, Kutarski A, Poterala M, Tomaszewski M, Brzozowski W, Kijima Y, Akagi T, Nakagawa K, Ikeda M, Watanabe N, Ueoka A, Takaya Y, Oe H, Toh N, Ito H, Bochard Villanueva B, Paya-Serrano R, Fabregat-Andres O, Garcia-Gonzalez P, Perez-Bosca J, Cubillos-Arango A, Chacon-Hernandez N, Higueras-Ortega L, De La Espriella-Juan R, Ridocci-Soriano F, Noack T, Mukherjee C, Ionasec R, Voigt I, Kiefer P, Hoebartner M, Misfeld M, Mohr FW, Seeburger J, Daraban AM, Baltussen L, Amzulescu M, Bogaert J, Jassens S, Voigt J, Duchateau N, Giraldeau G, Gabrielli L, Penela D, Evertz R, Mont L, Brugada J, Berruezo A, Bijnens B, Sitges M, Yoshikawa H, Suzuki M, Hashimoto G, Kusunose Y, Otsuka T, Nakamura M, Sugi K, Ruiz Ortiz M, Mesa D, Romo E, Delgado M, Seoane T, Martin M, Carrasco F, Lopez Granados A, Arizon J, Suarez De Lezo J, Magalhaes A, Cortez-Dias N, Silva D, Menezes M, Saraiva M, Santos L, Costa A, Costa L, Nunes Diogo A, Fiuza M, Ren B, De Groot-De Laat L, Mcghie J, Vletter W, Geleijnse M, Toda H, Oe H, Osawa K, Miyoshi T, Ugawa S, Toh N, Nakamura K, Kohno K, Morita H, Ito H, El Ghannudi S, Germain P, Samet H, Jeung M, Roy C, Gangi A, Orii M, Hirata K, Yamano T, Tanimoto T, Ino Y, Yamaguchi T, Kubo T, Imanishi T, Akasaka T, Sunbul M, Kivrak T, Oguz M, Ozguven S, Gungor S, Dede F, Turoglu H, Yildizeli B, Mutlu B, Mihaila S, Muraru D, Piasentini E, Peluso D, Cucchini U, Casablanca S, Naso P, Iliceto S, Vinereanu D, Badano L, Rodriguez Munoz D, Moya Mur J, Becker Filho D, Gonzalez A, Casas Rojo E, Garcia Martin A, Recio Vazquez M, Rincon L, Fernandez Golfin C, Zamorano Gomez J, Ledakowicz-Polak A, Polak L, Zielinska M, Kamiyama T, Nakade T, Nakamura Y, Ando T, Kirimura M, Inoue Y, Sasaki O, Nishioka T, Farouk H, Sakr B, Elchilali K, Said K, Sorour K, Salah H, Mahmoud G, Casanova Rodriguez C, Cano Carrizal R, Iglesias Del Valle D, Martin Penato Molina A, Garcia Garcia A, Prieto Moriche E, Alvarez Rubio J, De Juan Bagua J, Tejero Romero C, Plaza Perez I, Korlou P, Stefanidis A, Mpikakis N, Ikonomidis I, Anastasiadis S, Komninos K, Nikoloudi P, Margos P, Pentzeridis P. Poster session Thursday 12 December - AM: 12/12/2013, 08:30-12:30 * Location: Poster area. Eur Heart J Cardiovasc Imaging 2013. [DOI: 10.1093/ehjci/jet203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Bertrand P, Grieten L, Smeets C, Verbrugge F, Mullens W, Vrolix M, Rivero-Ayerza M, Verhaert D, Vandervoort P, Tong L, Ramalli A, Tortoli P, D'hoge J, Bajraktari G, Lindqvist P, Henein M, Obremska M, Boratynska M, Kurcz J, Zysko D, Baran T, Klinger M, Darahim K, Mueller H, Carballo D, Popova N, Vallee JP, Floria M, Chistol R, Tinica G, Grecu M, Rodriguez Serrano M, Osa-Saez A, Rueda-Soriano J, Buendia-Fuentes F, Domingo-Valero D, Igual-Munoz B, Alonso-Fernandez P, Quesada-Carmona A, Miro-Palau V, Palencia-Perez M, Bech-Hanssen O, Polte C, Lagerstrand K, Janulewicz M, Gao S, Erdogan E, Akkaya M, Bacaksiz A, Tasal A, Sonmez O, Turfan M, Kul S, Vatankulu M, Uyarel H, Goktekin O, Mincu R, Magda L, Mihaila S, Florescu M, Mihalcea D, Enescu O, Chiru A, Popescu B, Tiu C, Vinereanu D, Broch K, Kunszt G, Massey R, De Marchi S, Aakhus S, Gullestad L, Urheim S, Yuan L, Feng J, Jin X, Bombardini T, Casartelli M, Simon D, Gaspari M, Procaccio F, Hasselberg N, Haugaa K, Brunet A, Kongsgaard E, Donal E, Edvardsen T, Sahin T, Yurdakul S, Cengiz B, Bozkurt A, Aytekin S, Cesana F, Spano' F, Santambrogio G, Alloni M, Vallerio P, Salvetti M, Carerj S, Gaibazzi N, Rigo F, Moreo A, Wdowiak-Okrojek K, Michalski B, Kasprzak J, Shim A, Lipiec P, Generati G, Pellegrino M, Bandera F, Donghi V, Alfonzetti E, Guazzi M, Marcun R, Stankovic I, Farkas J, Vlahovic-Stipac A, Putnikovic B, Kadivec S, Kosnik M, Neskovic A, Lainscak M, Iliuta L, Szymanski P, Lipczynska M, Klisiewicz A, Sobieszczanska-Malek M, Zielinski T, Hoffman P, Gjerdalen GF, Hisdal J, Solberg E, Andersen T, Radunovic Z, Steine K, Svanadze A, Poteshkina N, Krylova N, Mogutova P, Shim A, Kasprzak J, Szymczyk E, Wdowiak-Okrojek K, Michalski B, Stefanczyk L, Lipiec P, Benedek T, Matei C, Jako B, Suciu Z, Benedek I, Yaroshchuk NA, Kochmasheva VV, Dityatev VP, Kerbikov OB, Przewlocka-Kosmala M, Orda A, Karolko B, Mysiak A, Kosmala W, Rechcinski T, Wierzbowska-Drabik K, Lipiec P, Chmiela M, Kasprzak J, Aziz A, Hooper J, Rayasamudra S, Uppal H, Asghar O, Potluri R, Zaroui A, Mourali M, Rezine Z, Mbarki S, Jemaa M, Aloui H, Mechmeche R, Farhati A, Gripari P, Maffessanti F, Tamborini G, Muratori M, Fusini L, Vignati C, Bartorelli A, Alamanni F, Agostoni P, Pepi M, Ruiz Ortiz M, Mesa D, Delgado M, Seoane T, Carrasco F, Martin M, Mazuelos F, Suarez De Lezo Herreros De Tejada J, Romero M, Suarez De Lezo J, Brili S, Stamatopoulos I, Misailidou M, Chrisochoou C, Christoforatou E, Stefanadis C, Ruiz Ortiz M, Mesa D, Delgado M, Martin M, Seoane T, Carrasco F, Ojeda S, Segura J, Pan M, Suarez De Lezo J, Cammalleri V, Ussia G, Muscoli S, Marchei M, Sergi D, Mazzotta E, Romeo F, Igual Munoz B, Bel Minguez A, Perez Guillen M, Maceira Gonzalez A, Monmeneu Menadas J, Hernandez Acuna C, Estornell Erill J, Lopez Lereu P, Francisco Jose Valera Martinez F, Montero Argudo A, Sunbul M, Akhundova A, Sari I, Erdogan O, Mutlu B, Cacicedo A, Velasco Del Castillo S, Anton Ladislao A, Aguirre Larracoechea U, Rodriguez Sanchez I, Subinas Elorriaga A, Oria Gonzalez G, Onaindia Gandarias J, Laraudogoitia Zaldumbide E, Lekuona Goya I, Ding W, Zhao Y, Lindqvist P, Nilson J, Winter R, Holmgren A, Ruck A, Henein M, Attenhofer Jost CH, Soyka R, Oxenius A, Kretschmar O, Valsangiacomo Buechel E, Greutmann M, Weber R, Keramida K, Kouris N, Kostopoulos V, Karidas V, Damaskos D, Makavos G, Paraskevopoulos K, Olympios C, Eskesen K, Olsen N, Fritz-Hansen T, Sogaard P, Cameli M, Lisi M, Righini F, Curci V, Massoni A, Natali B, Maccherini M, Chiavarelli M, Massetti M, Mondillo S, Mabrouk Salem Omar A, Ahmed Abdel-Rahman M, Khorshid H, Rifaie O, Santoro C, Santoro A, Ippolito R, De Palma D, De Stefano F, Muscariiello R, Galderisi M, Squeri A, Censi S, Baldelli M, Grattoni C, Cremonesi A, Bosi S, Saura Espin D, Gonzalez Canovas C, Gonzalez Carrillo J, Oliva Sandoval M, Caballero Jimenez L, Espinosa Garcia M, Garcia Navarro M, Valdes Chavarri M, De La Morena Valenzuela G, Ryu S, Shin D, Son J, Choi J, Goh C, Choi J, Park J, Hong G, Sklyanna O, Yuan L, Yuan L, Planinc I, Bagadur G, Ljubas J, Baricevic Z, Skoric B, Velagic V, Bijnens B, Milicic D, Cikes M, Gospodinova M, Chamova T, Guergueltcheva V, Ivanova R, Tournev I, Denchev S, Ancona R, Comenale Pinto S, Caso P, Arenga F, Coppola M, Calabro R, Neametalla H, Boitard S, Hamdi H, Planat-Benard V, Casteilla L, Li Z, Hagege A, Mericskay M, Menasche P, Agbulut O, Merlo M, Stolfo D, Anzini M, Negri F, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G, Stolfo D, Merlo M, Pinamonti B, Gigli M, Poli S, Porto A, Di Nora C, Barbati G, Di Lenarda A, Sinagra G, Coppola C, Piscopo G, Cipresso C, Rea D, Maurea C, Esposito E, Arra C, Maurea N, Nemes A, Kalapos A, Domsik P, Forster T, Voilliot D, Huttin O, Vaugrenard T, Schwartz J, Sellal JM, Aliot E, Juilliere Y, Selton-Suty C, Sanchez Millan PJ, Cabeza Lainez P, Castillo Ortiz J, Chueca Gonzalez E, Gheorghe L, Fernandez Garcia P, Herruzo Rojas M, Del Pozo Contreras R, Fernandez Garcia M, Vazquez Garcia R, Rosca M, Popescu B, Botezatu D, Calin A, Beladan C, Gurzun M, Enache R, Ginghina C, Farouk H, Al-Maimoony T, Alhadad A, El Serafi M, Abdel Ghany M, Poorzand H, Mirfeizi S, Javanbakht A, Tellatin S, Famoso G, Dassie F, Martini C, Osto E, Maffei P, Iliceto S, Tona F, Radunovic Z, Steine K, Jedrzejewska I, Braksator W, Krol W, Swiatowiec A, Sawicki J, Kostarska-Srokosz E, Dluzniewski M, Maceira Gonzalez AM, Cosin-Sales J, Diago J, Aguilar J, Ruvira J, Monmeneu J, Igual B, Lopez-Lereu M, Estornell J, Olszanecka A, Dragan A, Kawecka-Jaszcz K, Czarnecka D, Scholz F, Gaudron P, Hu K, Liu D, Florescu C, Herrmann S, Bijnens B, Ertl G, Stoerk S, Weidemann F, Krestjyaninov M, Razin V, Gimaev R, Bogdanovic Z, Burazor I, Deljanin Ilic M, Peluso D, Muraru D, Cucchini U, Mihaila S, Casablanca S, Pigatto E, Cozzi F, Punzi L, Badano L, Iliceto S, Zhdanova E, Rameev V, Safarova A, Moisseyev S, Kobalava Z, Magnino C, Omede' P, Avenatti E, Presutti D, Losano I, Moretti C, Bucca C, Gaita F, Veglio F, Milan A, Bellsham-Revell H, Bell A, Miller O, Simpson J, Hwang Y, Kim G, Jung M, Woo G, Driessen M, Leiner T, Schoof P, Breur J, Sieswerda G, Meijboom F, Bellsham-Revell H, Hayes N, Anderson D, Austin B, Razavi R, Greil G, Simpson J, Bell A, Zhao X, Xu X, Qin Y, Szmigielski CA, Styczynski G, Sobczynska M, Placha G, Kuch-Wocial A, Ikonomidis I, Voumbourakis A, Triantafyllidi H, Pavlidis G, Varoudi M, Papadakis I, Trivilou P, Paraskevaidis I, Anastasiou-Nana M, Lekakis I, Kong W, Yip J, Ling L, Milan A, Tosello F, Leone D, Bruno G, Losano I, Avenatti E, Sabia L, Veglio F, Zaborska B, Baran J, Pilichowska-Paszkiet E, Sikora-Frac M, Michalowska I, Kulakowski P, Budaj A, Mega S, Bono M, De Francesco V, Castiglione I, Ranocchi F, Casacalenda A, Goffredo C, Patti G, Di Sciascio G, Musumeci F, Kennedy M, Waterhouse D, Sheahan R, Foley D, Mcadam B, Ancona R, Comenale Pinto S, Caso P, Arenga F, Coppola M, Calabro R, Remme EW, Smedsrud MK, Hasselberg NE, Smiseth OA, Edvardsen T, Halmai L, Nemes A, Kardos A, Neubauer S, Degiovanni A, Baduena L, Dell'era G, Occhetta E, Marino P, Hotchi J, Yamada H, Nishio S, Bando M, Hayashi S, Hirata Y, Amano R, Soeki T, Wakatsuki T, Sata M, Lamia B, Molano L, Viacroze C, Cuvelier A, Muir J, Lipczynska M, Piotr Szymanski P, Anna Klisiewicz A, Lukasz Mazurkiewicz L, Piotr Hoffman P, Van 'T Sant J, Wijers S, Ter Horst I, Leenders G, Cramer M, Doevendans P, Meine M, Hatam N, Goetzenich A, Aljalloud A, Mischke K, Hoffmann R, Autschbach R, Sikora-Frac M, Zaborska B, Maciejewski P, Bednarz B, Budaj A, Evangelista A, Torromeo C, Pandian N, Nardinocchi P, Varano V, Schiariti M, Teresi L, Puddu P, Storve S, Dalen H, Snare S, Haugen B, Torp H, Fehri W, Mahfoudhi H, Mezni F, Annabi M, Taamallah K, Dahmani R, Haggui A, Hajlaoui N, Lahidheb D, Haouala H, Colombo A, Carminati M, Maffessanti F, Gripari P, Pepi M, Lang R, Caiani E, Walker J, Abadi S, Agmon Y, Carasso S, Aronson D, Mutlak D, Lessick J, Saxena A, Ramakrishnan S, Juneja R, Ljubas J, Reskovic Luksic V, Matasic R, Pezo Nikolic B, Lovric D, Separovic Hanzevacki J, Quattrone A, Zito C, Alongi G, Vizzari G, Bitto A, De Caridi G, Greco M, Tripodi R, Pizzino G, Carerj S, Ibrahimi P, Jashari F, Johansson E, Gronlund C, Bajraktari G, Wester P, Henein M, Kosmala W, Marwick T, Souza JRM, Zacharias LGT, Geloneze B, Pareja JC, Chaim A, Nadruz WJ, Coelho OR, Apostolovic S, Stanojevic D, Jankovic-Tomasevic R, Salinger-Martinovic S, Djordjevic-Radojkovic D, Pavlovic M, Tahirovic E, Musial-Bright L, Lainscak M, Duengen H, Filipiak D, Kasprzak J, Lipiec P. Poster session Wednesday 11 December all day display: 11/12/2013, 09:30-16:00 * Location: Poster area. Eur Heart J Cardiovasc Imaging 2013. [DOI: 10.1093/ehjci/jet202] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Helvacioglu F, Yildirimturk O, Duran C, Yurdakul S, Tayyareci Y, Ulusoy OL, Aytekin S. The evaluation of mitral valve stenosis: comparison of transthoracic echocardiography and cardiac magnetic resonance. Eur Heart J Cardiovasc Imaging 2013; 15:164-9. [DOI: 10.1093/ehjci/jet087] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
|
37
|
Yurdakul S, Cengiz B, Sahin T, Bozkurt A, Aytekin S. Impairment in aortic elastic properties and mechanics of ascending aorta in patients with bicuspid aortic valve. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht310.p4760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Aytekin S, Yurdakul S, Tayyareci Y, Yildirimturk O, Ezelsoy M, Bayramoglu Z, Sagbas E, Altuntas E, Akpinar B, Aytekin V. Evaluation of graft patency after coronary artery bypass grafting by using stress echocardiography combined with strain imaging. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht310.p5109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
39
|
Yurdakul S, Bingol ZK, Sahin T, Cengiz B, Bozkurt A, Kiyan E, Aytekin S. Left ventricular rotational deformation is impaired in pulmonary hypertension: a speckle tracking- based study. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht307.p333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Caglar E, Ugurlu S, Seyahi E, Kantarci F, Sonsuz A, Yurdakul S, Yazici H. SAT0178 An Outcome Survey of 40 Patients with Budd-Chiari Syndrome due to BehÇEt’S Syndrome Followed by a Single Center. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
41
|
Alibaz-Oner F, Yurdakul S, Tayyareci Y, Direskeneli H, Aytekin S. AB1252 Subclinical left ventricular systolic dysfunction in patients with takayasu’s arteritis. A velocity vector imaging-based study. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
42
|
Alibaz-Oner F, Yurdakul S, Tayyareci Y, Direskeneli H, Aytekin S. SAT0399 Impairment in aortic elastic properties and mechanics of carotid artery system in patients with takayasu’ s arteritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.3345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
43
|
Yurdakul S, Nezhdi Mustafa B, Fresko I, Seyahi E, Yazici H. SAT0562 The Consort Criteria for Eligibilty, Study Settings, Locations, and Center Effects are Seldom Met in Randomised Clinical Trials. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
44
|
Ozguler Y, Pala AS, Hamuryudan V, Hatemi G, Yurdakul S, Yazici H. AB0483 Causes of hospitalisation in behcet’s syndrome over a ten-year period. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
45
|
Hamuryudan V, Hatemi G, Ozyazgan Y, Ucar D, Yurdakul S, Seyahi E, Tascilar K, Ugurlu S, Yazici H. FRI0337 Infliximab for sight-threatening and refractory uveitis of behçet’s syndrome. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
46
|
Buyuktas D, Hatemi G, Yuksel Findikoglu S, Tascilar K, Ugurlu S, Yurdakul S. THU0208 Fatigue is an important problem in patients with behcet’s syndrome:. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
47
|
Alibaz-Oner F, Yurdakul S, Aytekin S, Direskeneli H. FRI0358 Impaired endothelial function in patients with takayasu’s arteritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
48
|
Alibaz-Oner F, Yurdakul S, Sahin T, Direskeneli H, Aytekin S. FRI0497 Subclinical left ventricular systolic dysfunction is present in patients with systemic lupus erythematosus with normal conventional echocardiographic assessment: a speckle tracking and real time three dimensional echocardiographic study. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1624] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
49
|
Alibaz-Oner F, Yurdakul S, Aytekin S, Direskeneli H. Impairment in aortic elastic properties and mechanics of carotid artery system in patients with Takayasu's arteritis. Presse Med 2013. [DOI: 10.1016/j.lpm.2013.02.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
50
|
Altman M, Bergerot C, Thibault H, Aussoleil A, Skuldadt Davidsen E, Barthelet M, Derumeaux GA, Grapsa J, Zimbarra Cabrita I, Afilalo J, Paschou S, Dawson D, Durighel G, O'regan D, Howard L, Gibbs J, Nihoyannopoulos P, Morenate Navio M, Mesa Rubio M, Ortega MD, Ruiz Ortiz M, Castillo Bernal F, Del Pino CL, Toledano F, Alvarez-Ossorio MP, Ojeda Pineda S, Lezo Cruz-Conde JSD, Jasaityte R, Claus P, Teske A, Herbots L, Verheyden B, Rademakers F, D'hooge J, Tocchetti CG, Coppola C, Rea D, Quintavalle C, Guarino L, Castaldo N, De Lorenzo C, Condorelli G, Arra C, Maurea N, Voilliot D, Huttin O, Camara Y, Djaballah W, Carillo S, Zinzius P, Sellal J, Angioi M, Juilliere Y, Selton-Suty C, Dobrowolski P, Klisiewicz A, Florczak E, Prejbisz A, Szwench E, Rybicka J, Januszewicz A, Hoffman P, Jurado Roman A, De Dios Perez S, De Nicolas JMM, Diaz Anton B, Rubio Alonso B, Martin Asenjo R, Mayordomo Gomez S, Villagraz Tecedor L, Blazquez L, De Meneses RT, Bernard A, Hernandez AI, Reynaud A, Lerclercq C, Daubert J, Donal E, Arjan Singh R, Sivarani S, Lim S, Azman W, Almeida M, Cardim N, Fonseca V, Carmelo V, Santos S, Santos T, Toste J, Kosmala W, Orda A, Karolko B, Mysiak A, Przewlocka-Kosmala M, Farsalinos K, Tsiapras D, Kyrzopoulos S, Avramidou E, Vassilopoulou D, Voudris V, Hayrapetyan H, Adamyan K, Jurado Roman A, De Dios Perez S, Rubio Alonso B, De Nicolas JMM, Diaz Anton B, Martin Asenjo R, Montero Cabezas J, Granda Nistal C, Garcia Aranda B, Sanchez Sanchez V, Sestito A, Lamendola P, Di Franco A, Lauria C, Lanza G, Kukucka M, Unbehaun A, Buz S, Mladenow A, Kuppe H, Pasic M, Habazettl H, Gemma D, Montoro Lopez N, De Celix MGR, Lopez Fernandez T, De Torres Alba F, Del Valle DI, Ramirez U, Mesa J, Moreno Yanguela M, Lopez Sendon J, Eveborn GW, Schirmer H, Lunde P, Heggelund G, Rasmussen K, Wang Z, Lasota B, Mizia-Stec K, Mizia M, Chmiel A, Adamczyk T, Chudek J, Gasior Z, Venkatesh A, Johnson J, Sahlen A, Brodin L, Winter R, Shahgaldi K, Manouras A, Valbuena S, Iniesta A, Lopez T, De Torres F, Salinas P, Garcia S, Ramirez U, Mesa J, Moreno M, Lopez-Sendon J, Lebid I, Kobets T, Kuzmenko T, Katsanos S, Yiu K, Clavel M, Nina Ajmone N, Van Der Kley F, Rodes Cabau J, Schalij M, Bax J, Pibarot P, Delgado V, Fusini L, Tamborini G, Muratori M, Gripari P, Marsan N, Cefalu' C, Ewe S, Maffessanti F, Delgado V, Pepi M, Hasselberg N, Haugaa K, Petri H, Berge K, Leren T, Bundgaard H, Edvardsen T, Ancona R, Comenale Pinto S, Caso P, Coppola M, Rapisarda O, Cavallaro C, Vecchione F, D'onofrio A, Calabro' R, Rimbas R, Mihaila S, Enescu O, Patrascu N, Dragoi R, Rimbas M, Pop C, Vinereanu D, Gustafsson S, Morner S, Gronlund C, Suhr O, Lindqvist P, Di Bella G, Zito C, Minutoli F, Madaffari A, Cusma Piccione M, Mazzeo A, Massimo R, Pasquale M, Vita G, Carerj S, Rangel I, Goncalves A, Sousa C, Correia A, Martins E, Silva-Cardoso J, Macedo F, Maciel M, Pfeiffer B, Rigopoulos A, Seggewiss H, Alvarez Fuente M, Sainz Costa T, Medrano C, Navarro M, Blazquez Gamero D, Ramos J, Mellado M, De Jose M, Munoz M, Maroto E, Gargani L, Gosciniak P, Pratali L, Agoston G, Bruni C, Guiducci S, Matucci Cerinic M, Varga A, Sicari R, Picano E, Yiu K, Zhao C, Mei M, Yeung C, Siu C, Tse H, Florescu M, Enescu O, Magda L, Mincu R, Vinereanu D, Daha I, Stanescu CM, Chirila L, Baicus C, Vlase A, Dan G, Montoro Lopez M, Florez Gomez R, Alonso Ladreda A, Itziar Soto C, Rios Blanco J, Gemma D, De Torres Alba F, Moreno Yanguela M, Lopez Sendon J, Guzman Martinez G, Lichodziejewska B, Kurnicka K, Goliszek S, Kostrubiec M, Dzikowska-Diduch O, Ciurzynski M, Labyk A, Krupa M, Palczewski P, Pruszczyk P, De Sousa CC, Rangel I, Correia A, Martins E, Vigario A, Pinho T, Silva Cardoso J, Goncalves A, Macedo F, Maciel M, Park SJ, Song JE, Lee YJ, Ha MR, Chang SA, Choi JO, Lee SC, Park S, Oh J, Van De Bruaene A, De Meester P, Buys R, Vanhees L, Delcroix M, Voigt J, Budts W, Blundo A, Buccheri S, Monte IP, Leggio S, Tamburino C, Sotaquira M, Fusini L, Maffessanti F, Pepi M, Lang R, Caiani E, Floria M, De Roy L, Xhaet O, Blommaert D, Jamart J, Gerard M, Deceuninck O, Marchandise B, Seldrum S, Schroeder E, Unsworth B, Sohaib S, Kulwant-Kaur K, Malcolme-Lawes L, Kanagaratnam P, Malik I, Ren B, Mulder H, Haak A, Van Stralen M, Szili-Torok T, Pluim J, Geleijnse M, Bosch J, Baglini R, Amaducci A, D'ancona G, Van Den Oord S, Akkus Z, Bosch J, Ten Kate G, Renaud G, Sijbrands E, De Jong N, Van Der Lugt A, Van Der Steen A, Schinkel A, Bjallmark A, Larsson M, Grishenkov D, Brodin LA, Brismar T, Paradossi G, Sveen KA, Nerdrum T, Hanssen K, Dahl-Jorgensen K, Steine K, Cimino S, Pedrizzetti G, Tonti G, Canali E, Petronilli V, Cicogna F, Arcari L, De Luca L, Iacoboni C, Agati L, Abdel Moneim SS, Eifert Rain S, Bernier M, Bhat G, Hagen M, Bott-Kitslaar D, Castello R, Wilansky S, Pellikka P, Mulvagh S, Delithanasis I, Celutkiene J, Kenny C, Monaghan M, Park W, Hong G, Son J, Lee S, Kim U, Park J, Shin D, Kim Y, Toutouzas K, Drakopoulou M, Aggeli C, Felekos I, Nikolaou C, Synetos A, Stathogiannis K, Tsiamis E, Siores E, Stefanadis C, Plicht B, Kahlert P, Grave T, Buck T, Konorza T, Gursoy M, Gokdeniz T, Astarcioglu M, Bayram Z, Cakal B, Karakoyun S, Kalcik M, Acar R, Kahveci G, Ozkan M, Maffessanti F, Tamborini G, Tsang W, Weinert L, Gripari P, Fusini L, Muratori M, Caiani E, Lang R, Pepi M, Yurdakul S, Avci B, Sahin S, Dilekci B, Aytekin S, Ancona R, Comenale Pinto S, Caso P, Arenga F, Coppola M, Rapisarda O, Calabro' R, Hascoet S, Martin R, Dulac Y, Peyre M, Benzouid C, Hadeed K, Acar P, Celutkiene J, Zakarkaite D, Skorniakov V, Zvironaite V, Grabauskiene V, Burca J, Ciparyte L, Laucevicius A, Di Salvo G, Rea A, D'aiello A, Del Gaizo F, Pergola V, D'andrea A, Caso P, Pacileo G, Calabro R, Russo M, Dedobbeleer C, Hadefi A, Naeije R, Unger P, Mornos C, Cozma D, Ionac A, Mornos A, Valcovici M, Pescariu S, Petrescu L, Hu K, Liu D, Niemann M, Herrmann S, Cikes M, Stoerk S, Knop S, Ertl G, Bijnens B, Weidemann F, De Knegt M, Biering-Sorensen T, Sogaard P, Sivertsen J, Jensen J, Mogelvang R, Dedobbeleer C, Hadefi A, Unger P, Naeije R, Lam W, Tang M, Chan K, Yang Y, Fang F, Sun J, Yu C, Lam Y, Panoulas V, Sulemane S, Bratsas A, Konstantinou K, Nihoyannopoulos P, Cimino S, Canali E, Petronilli V, Cicogna F, Arcari L, De Luca L, Francone M, Iacoboni C, Agati L, Schau T, Seifert M, Ridjab D, Schoep M, Gottwald M, Neuss M, Meyhoefer J, Zaenker M, Butter C, Tarr A, Stoebe S, Pfeiffer D, Hagendorff A, Maret E, Ahlander BM, Bjorklund PG, Engvall J, Staskiewicz G, Czekajska-Chehab E, Adamczyk P, Siek E, Przybylski P, Maciejewski R, Drop A, Jimenez Rubio C, Isasti Aizpurua G, Miralles Ibarra J, Al-Mallah M, Somg T, Alam S, Chattahi J, Zweig B, Dhanalakota K, Boedeker S, Ananthasubramaniam K, Park C, March K, Jones S, Mayet J, Tillin T, Chaturvedi N, Hughes A, Hamodraka E, Kallistratos E, Karamanou A, Tsoukas T, Mavropoulos D, Kouremenos N, Zaharopoulou I, Nikolaidis N, Kremastinos D, Manolis A, Loboz-Rudnicka M, Jaroch J, Bociaga Z, Kruszynska E, Ciecierzynska B, Dziuba M, Dudek K, Uchmanowicz I, Loboz-Grudzien K, Silva D, Magalhaes A, Jorge C, Cortez-Dias N, Carrilho-Ferreira P, Silva Marques J, Portela I, Pascoa C, Nunes Diogo A, Brito D, Roosens B, Bala G, Droogmans S, Hostens J, Somja J, Delvenne E, Schiettecatte J, Lahoutte T, Van Camp G, Cosyns B. Poster Session: Right ventricular systolic function. Eur Heart J Cardiovasc Imaging 2012. [DOI: 10.1093/ehjci/jes268] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|